WO2018153545A1

WO2018153545A1 - Piperidine methanone derivatives having multimodal activity against pain

Info

Publication number: WO2018153545A1
Application number: PCT/EP2018/000078
Authority: WO
Inventors: Carmen ALMANSA-ROSALES; Monica Garcia-Lopez; Ute Christmann
Original assignee: Laboratorios Del Dr. Esteve, S.A.
Priority date: 2017-02-27
Filing date: 2018-02-27
Publication date: 2018-08-30

Abstract

The present invention relates piperidine methanone derivatives having dual pharmacological activity towards both the sigma (a) receptor, and the μ-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Description

PIPERIDINE METHANONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN.

FIELD OF THE INVENTION

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor (MOR or mu-opioid receptor) and more particularly to piperidine methanone derivatives having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain. BACKGROUND OF THE INVENTION

The adequate management of pain constitutes an important challenge, since currently available treatments provide in many cases only modest improvements, leaving many patients unrelieved [Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet 377, 2226-2235 (2011)]. Pain affects a big portion of the population with an estimated prevalence of around 20% and its incidence, particularly in the case of chronic pain, is increasing due to the population ageing. Additionally, pain is clearly related to comorbidities, such as depression, anxiety and insomnia, which lead to important productivity losses and socio-economic burden [Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health. 11 , 770 (2011)]. Existing pain therapies include non-steroidal anti-inflammatory drugs (NSAIDs), opioid agonists, calcium channel blockers and antidepressants, but they are much less than optimal regarding their safety ratio. All of them show limited efficacy and a range of secondary effects that preclude their use, especially in chronic settings.

As mentioned before, there are few available therapeutic classes for the treatment of pain, and opioids are among the most effective, especially when addressing severe pain states. They act through three different types of opioid receptors (mu, kappa and gamma) which are transmembrane G-protein coupled receptors (GPCRs). Still, the main analgesic action is attributed to the activation of the μ-opioid receptor (MOR). However, the general administration of MOR agonists is limited due to their important side effects, such as constipation, respiratory depression, tolerance, emesis and physical dependence [Meldrum, M.L. (Ed.). Opioids and Pain Relief: A Historical Perspective. Progress in Pain Research and Management, Vol 25. IASP Press, Seattle, 2003]. Additionally, MOR agonists are not optimal for the treatment of chronic pain as indicated by the diminished effectiveness of morphine against chronic pain conditions. This is especially proven for the chronic pain conditions of neuropathic or inflammatory origin, in comparison to its high potency against acute pain. The finding that chronic pain can lead to MOR down-regulation may offer a molecular basis for the relative lack of efficacy of morphine in long-term treatment settings [Dickenson, A.H., Suzuki, R. Opioids in neuropathic pain: Clues from animal studies. Eur J Pain 9, 113-6 (2005)]. Moreover, prolonged treatment with morphine may result in tolerance to its analgesic effects, most likely due to treatment-induced MOR down-regulation, internalization and other regulatory mechanisms. As a consequence, long-term treatment can result in substantial increases in dosing in order to maintain a clinically satisfactory pain relief, but the narrow therapeutic window of MOR agonists finally results in unacceptable side effects and poor patient compliance.

The sigma- 1 (σι) receptor was discovered 35 years ago and initially assigned to a new subtype of the opioid family, but later on and based on the studies of the enantiomers of SKF-10,047, its independent nature was established. The first link of the σ₁ receptor to analgesia was established by Chien and Pasternak [Chien CC, Pasternak GW. Sigma antagonists potentiate opioid analgesia in rats. Neurosci. Lett. 190, 137-9 (1995)], who described it as an endogenous anti-opioid system, based on the finding that σ₁ receptor agonists counteracted opioid receptor mediated analgesia, while σι receptor antagonists, such as haloperidol, potentiated it.

Many additional preclinical evidences have indicated a clear role of the σ₁ receptor in the treatment of pain [Zamanillo D, Romero L, Merlos M, Vela JM. Sigma 1 receptor: A new therapeutic target for pain. Eur. J. Pharmacol, 716, 78-93 (2013)]. The development of the σ₁ receptor knockout mice, which show no obvious phenotype and perceive normally sensory stimuli, was a key milestone in this endeavour. In physiological conditions the responses of the σ₁ receptor knockout mice to mechanical and thermal stimuli were found to be undistinguishable from WT ones but they were shown to possess a much higher resistance to develop pain behaviours than WT mice when hypersensitivity entered into play. Hence, in the σ₁ receptor knockout mice capsaicin did not induce mechanical hypersensitivity, both phases of formalin-induced pain were reduced, and cold and mechanical hypersensitivity were strongly attenuated after partial sciatic nerve ligation or after treatment with paclitaxel, which are models of neuropathic pain. Many of these actions were confirmed by the use of σ₁ receptor antagonists and led to the advancement of one compound, S1 RA, into clinical trials for the treatment of different pain states. Compound S1 RA exerted a substantial reduction of neuropathic pain and anhedonic state following nerve injury (i.e., neuropathic pain conditions) and, as demonstrated in an operant self-administration model, the nerve- injured mice, but not sham-operated mice, acquired the operant responding to obtain it (presumably to get pain relief), indicating that σ₁ receptor antagonism relieves neuropathic pain and also address some of the comorbidities (i.e., anhedonia, a core symptom in depression) related to pain states.

Pain is multimodal in nature, since in nearly all pain states several mediators, signalling pathways and molecular mechanisms are implicated. Consequently, monomodal therapies fail to provide complete pain relief. Currently, combining existing therapies is a common clinical practice and many efforts are directed to assess the best combination of available drugs in clinical studies [Mao J, Gold MS, Backonja M. Combination drug therapy for chronic pain: a call for more clinical studies. J. Pain 12, 157-166 (2011)]. Hence, there is an urgent need for innovative therapeutics to address this unmet medical need.

As mentioned previously, opioids are among the most potent analgesics but they are also responsible for various adverse effects which seriously limit their use.

Accordingly, there is still a need to find compounds that have an alternative or improved pharmacological activity in the treatment of pain, being both effective and showing the desired selectivity, and having good "drugability" properties, i.e. good pharmaceutical properties related to administration, distribution, metabolism and excretion.

Thus, the technical problem can therefore be formulated as finding compounds that have an alternative or improved pharmacological activity in the treatment of pain.

In view of the existing results of the currently available therapies and clinical practices, the present invention offers a solution by combining in a single compound binding to two different receptors relevant for the treatment of pain. This was mainly achieved by providing the compounds according to the invention that bind both to the μ-opioid receptor and to the σ₁ receptor.

SUMMARY OF THE INVENTION

The main object of the invention is in one aspect directed to piperidine methanone derivatives having a dual activity binding to the σ₁ receptor and the μ-opioid receptor for use in the treatment of pain.

As this invention is aimed at providing a compound or a chemically related series of compounds which act as dual ligands of the σ₁ receptor and the μ-opioid receptor it is a very preferred embodiment if the compound has a binding expressed as Kj which is preferably < 1000 nM for both receptors, more preferably < 500 nM, even more preferably < 100 nM.

More particularly the main aspect of the invention refers to a compound of general Formula (I),

wherein R₁, R₂, R₃, R₄, ₄,. R₄,,, R_{4 ' "} , X, Y, W, m, n, q and r are as defined below in the detailed description.

A further object of the invention refers to the processes for preparation of compounds of general formula (I).

A still further object of the invention refers to the use of some intermediate compounds for the preparation of a compound of general formula (I). It is also an object of the invention a pharmaceutical composition comprising a compound of formula (I).

Finally, it is an object of the invention the use of compound as a medicament and more particularly for the treatment of pain and pain related conditions.

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to a family of structurally distinct to piperidine methanone derivatives which have a dual pharmacological activity towards both the sigma (σ) receptor and the μ-opioid receptor, thus solving the above problem of identifying alternative or improved pain treatments by offering such dual compounds.

The invention is directed to compounds having a dual activity binding to the σ₁ receptor and the μ-opioid receptor for use in the treatment of pain.

As this invention is aimed at providing a compound or a chemically related series of compounds which act as dual ligands of the σ₁ receptor and the μ-opioid receptor it is a preferred embodiment if the compound has a binding expressed as K, which is preferably < 1000 nM for both receptors, more preferably < 500 nM, even more preferably < 100 nM.

The applicant has surprisingly found that the problem of providing a new effective and alternative for treating pain and pain related disorders can be solved by using a multimodal balanced analgesic approach combining two different synergistic activities in a single drug (i.e., dual ligands which are bifunctional and bind to μ-opioid receptor and to σ₁ receptor), thereby enhancing the opioid analgesia through the σ₁ activation without increasing the undesirable side effects. This supports the therapeutic value of a dual MOR/ σ₁ receptor compound whereby the σ₁ receptor binding component acts as an intrinsic adjuvant of the MOR binding component.

This solution offered the advantage that the two mechanisms complement each other in order to treat pain and chronic pain using lower and better tolerated doses needed based on the potentiation of analgesia but avoiding the adverse events of μ-opioid receptor agonists.

A dual compound that possess binding to both the μ-opioid receptor and to the σι receptor shows a highly valuable therapeutic potential by achieving an outstanding analgesia (enhanced in respect to the potency of the opioid component alone) with a reduced side-effect profile (safety margin increased compared to that of the opioid component alone) versus existing opioid therapies.

Advantageously, the dual compounds according to the present invention would show one or more the following functionalities: σ₁ receptor antagonism and μ-opioid receptor agonism. It has to be noted, though, that both functionalities "antagonism" and "agonism" are also sub-divided in their effect into subfunctionalities like partial agonism or inverse agonism. Accordingly, the functionalities of the dual compound should be considered within a relatively broad bandwidth.

An antagonist on one of the named receptors blocks or dampens agonist-mediated responses. Known subfunctionalities are neutral antagonists or inverse agonists.

An agonist on one of the named receptors increases the activity of the receptor above its basal level. Known subfunctionalities are full agonists, or partial agonists.

In addition, the two mechanisms complement each other since MOR agonists are only marginally effective in the treatment of neuropathic pain, while σ₁ receptor antagonists show outstanding effects in preclinical neuropathic pain models. Thus, the σ₁ receptor component adds unique analgesic actions in opioid-resistant pain. Finally, the dual approach has clear advantages over MOR agonists in the treatment of chronic pain as lower and better tolerated doses would be needed based on the potentiation of analgesia but not of the adverse events of MOR agonists. A further advantage of using designed multiple ligands is a lower risk of drug-drug interactions compared to cocktails or multi-component drugs, thus involving simpler pharmacokinetics and less variability among patients. Additionally, this approach may improve patient compliance and broaden the therapeutic application in relation to monomechanistic drugs, by addressing more complex aetiologies. It is also seen as a way of improving the R&D output obtained using the "one drug-one target" approach, which has been questioned over the last years [Bornot A, Bauer U, Brown A, Firth M, Hellawell C, Engkvist O. Systematic Exploration of Dual-Acting Modulators from a Combined Medicinal Chemistry and Biology Perspective. J. Med. Chem, 56, 1197-1210 (2013)].

In its broader aspect, the present invention is directed to compounds of general Formula (I):

(I) wherein m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1 , 2 or 3; q is 0, 1 , 2 or 3; X is a bond or -0-;

W is -CH- or nitrogen;

Y is a bond or -0-; R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl,

R₃ is selected from hydrogen, substituted or unsubstituted C₁-β alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄ and R₄, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄ and R₄, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R₄ and R₄, may form together with the carbon atom to which they are attached a carbonyl group; R₄, and F are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄,, and R₄,,,, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl.

These compounds according to the invention are optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another embodiment, these compounds according to the invention are optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a particular embodiment, the following proviso applies: when Y is -0-, then m is 1 or 2.

In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (I^,)

(I^,),

wherein R₁, R2, R3, R4, R₄,,, R₄,,, R₄,,,, X, W, m, n, q and r are as defined below in the detailed description; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (la')

wherein R₁, R₂, R₃, R₄, R₄,. R₄,,, R_{4 ' "} , X, W, m, q and r are as defined below in the detailed description; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (I²')

(I²').

wherein R2, R3, R4, R₄,,, R₄,,, R₄,,,,, X, W, m, n, q and r are as defined below in the detailed description, and wherein R₃ and R₃- are independently selected from halogen, -R₁₄, -OR₁₁, -NO2, -NR₁₁R₁r, -NR₁₁C(0)R₁r, -NR₁₁S(0)2R₁r, - S(0)₂NR₁₁R₁r, -NR₁₁C(0)NR,rR₁r, -SR₁₁ , -S(0)R₁₁, -S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, -C(0)NR₁₁R₁r, -OCH2CH2OR11, -NR₁₁S(0)2NR₁rR₁r and -C(CH₃)20R₁₁; and R11, R₁₄,,and R₁₁ - are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl. optionally in form of one of the stereoisomers, preferably enantiomers or

diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (I³')

(I³'),

wherein R2, R3, R4, R₄,, Re, R4-, X, W, m, q and r are as defined below in the detailed description, and wherein R₃ and R₃- are independently selected from halogen, -R₁₁, -OR₁₁, -NO2, -NR₁₁R₁r, -NR₁₁C(0)R₁r, -NR₁₁S(0)₂R₁r, - S(0)₂NR₁₁R₁r, -NR₁₁C(0)NR₁rR₁₁,, -SR₁₁ , -S(0)R₁₁, -S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, -C(0)NR₁₁R₁r, -OCH2CH2OR11, -NR₁₁S(0)₂NR₁₁ R₁₁ - and -C(CH₃)20R₁₁; and R11, R₁₁ and R₁₁ - are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl. optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (I⁴')

wherein R₂, R3, R₄,-, R₄,-, X, W, m, q and r are as defined below in the detailed description, and wherein R₃ andR₆ - are independently selected from halogen, - R₁₁, -OR₁₁, -NO2, -NR₁₁R,v, -NR₁₁C(0)R₁r, -NR₁₁S(0)₂R₁₁-, -S(0)₂NR₁₁R₁r, - NR₁₁C(0)NR₁rR₁r, -SR₁₁ , -S(0)R₁₁, S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, - C(0)OR₁₁, -C(0)NR₁₁R₁₁,, -OCH₂CH₂OR₁₁, -NR₁₁S(0)₂NR₁₁ R_1r and - C(CH₃)₂OR₁₁; and R11, R₁₁,,and R₁₁, are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl. optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof. In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (l^Sa')

R₃

wherein R2, R3, R₄,, R₄,,,, X, m, q and r are as defined below in the detailed description, and whereRin₆ andR₆ - are independently selected from halogen, - R₁₁, -OR11, -NO2, -NR₁₁R₁₁,, -NR₁₁C(0)R₁r, -NR₁₁S(0)₂R₁r, -S(0)₂NR₁₁R₁r, - NR₁₁C(0)NR₁₁ R₁₁", -SR₁₁ , -S(0)R₁₁, S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -

C(0)OR₁₁, -C(0)NR₁₁R₁₁-, -OCH2CH2OR11, -NR₁₁S(0)₂NR₁rR₁₁, and - C(CH₃)₂OR₁₁; and R11, R₁₁,, and R₁₁, are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl. optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof. In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (l^5b')

wherein R2, R3, R₄,,, R₄,,,, X, m, q and r are as defined below in the detailed description, andR₆ andR₆ - are independently selected from halogen, -R₁₁, - OR11, -NO2, -NR₁₁R₁r, -NR₁₁C(0)R₁r, -NR₁₁S(0)₂R₁₁,, -S(0)₂NR₁,R₁r, - NR₁₁C(0)NR₁₁,R₁r, -SR₁₁ , -S(0)R₁₁, S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, - C(0)OR₁₁, -C(0)NR₁₁R₁r, -OCH2CH2OR11, -NR₁₁S(0)₂NR₁₁ R₁r and - C(CH₃)20R₁₁; and R11, R₁₁,,and R₁₁, are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl. optionally in form of one of the stereoisomers, preferably enantiomers or

In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (l^6a')

wherein R2, R3, R₄,, R₄,,,, m, q and r are as defined below in the detailed description, and whereRin₆ andR₆ - are independently selected from halogen, - R₁₁, -OR11, -N0_2l -NR₁₁R₁r, -NR₁₁C(0)R₁r, -NR₁₁S(0)₂R₁₁-, -S(0)₂NR₁₁R,v, - NR₁₁C(0)NR₁₁,R₁₁--, -SR₁₁ , -S(0)R₁₁, S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, - C(0)OR₁₁, -C(0)NR₁₁R₁r, -OCH₂CH₂OR₁₁, -NR₁₁S(0)₂NR₁₁,R₁₁- and - C(CH₃)₂OR₁₁; and R11, R₁r and R₁₁- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl. optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (l^eb')

wherein R2, R3, R₄,,, R₄,,,, m, q and r are as defined below in the detailed description, and whereiRn₆ andR₆ - are independently selected from halogen, - R₁₁, -OR11, -NO2, -NR₁₁R₁r, -NR₁₁C(0)R₁r, -NR₁₁S(0)₂R₁₁,, -S(0)₂NR₁₁R₁r, - NR₁₁C(0)NR₁rR₁v, -SR₁₁ , -S(0)R₁₁, S(0)₂R₁₄,, -CN, haloalkyl, haloalkoxy, - C(0)OR₁₁, -C(0)NR₁₁R₁₁,, -OCH2CH₂OR₁₁, -NR₁₁S(0)₂NR₁₁,R₁₄ ' " and - C(CH₃)₂OR₁₁; and R11, R₁₁- and R₁₁,, are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl. optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (I⁷')

wherein R₁. R2, R3, R₄,-, R₄,,,, X, Y, W, m, n, q and r are as defined below in the detailed description, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound of general Formula (I⁸')

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

For clarity purposes, all groups and definitions described in the description and referring to compounds of general Formula (I), also apply to compounds of general Formula (I^,), (la'), (I²'), (I³'), (I⁴¹), (I⁵⁸'), (l^5b'), (I⁶"'), (l^eb'), (I⁷') and (I⁸'), as well as to all the intermediates of synthesis, when those groups are present in the mentioned general Markush formulae, since compounds of general (I^,), (la'), (I²'), (I³'), (I⁴'), (I⁵⁸'), (l^5b'), (I₄,"), (l^eb'), (I⁷') and (I⁸'), are included within the scope of the larger definition of general Formula (I)-

wherein only the -CH₂- groups are included into the brackets and m, n, q or r mean the number of times that said -CH₂- groups are repeated. The same would apply, when applicable, to general Markush Formulae (I^,), (la'), (I²'), (I³'), (I⁴'), (Ι^5β'), (l^5b'), (I⁶⁸'), (l^6b'), (I⁷') and (I⁸'), and to all intermediates of synthesis.

In addition, and for clarity purposes, it should further be understood that naturally if m is 0, then the rest of the cycle is still present, when applicable, in general Markush Formulae (I), (I^,), (la"), (I²'). (I³'). (I⁴'). (I^5a'), fl^5b'). (Ι^β3'). (I^eb"). (I⁷') and (I⁸'), and to all intermediates of synthesis.

In the same way, if r is 0, then the rest of the cycle still present, when applicable, in general Markush Formulae (I), (I^,), (la"), (I²'), (I³'), (I⁴'), (l^5a'), (l^5b'), (l^6a'), (l^6b"), (I⁷') and (I⁸'), and to all intermediates of synthesis. It should also be understood that naturally if n is 0, then W is still present, when applicable, in general Markush Formulae (I), (I^,), (I²'). (I⁷') and (l⁸').

It should also be understood that if q is 0, then the piperidine/piperazine cycle and X/O or R₂ are still present in general Markush Formulae (I), (I^,), (la'), (I²'), (I³'), (I⁴'). (I⁵³'). (l^5b'), (I⁶⁸'), (l^eb'). (I⁷') and (I⁸').

In the context of this invention, alkyl is understood as meaning saturated, linear or branched hydrocarbons, which may be unsubstituted or substituted once or several times. It encompasses e.g. -CH₃ and -CH2-CH3. In these radicals, C₁-2-alkyl represents C1- or C2-alkyl, C₁-3-alkyl represents C1-, C2- or C3-alkyl, C₁-4-alkyl represents C1-, C2-, C3- or C4-alkyl, C₁-5-alkyl represents C1-, C2-, C3-, C4-, or C5-alkyl, C_1-6-alkyl represents C1-, C2-, C3-, C4-, C5- or C6-alkyl, C₁-7-alkyl represents C1-, C2-, C3-, C4- , C5-, C6- or C7-alkyl, C_1-6-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7- or C8- alkyl, C₁-io-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9- or C10-alkyl and C₁-ie-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, C10-, C11-, C12-, C13-, C14-, C15-, C16-, C17- or C18-alkyl. The alkyl radicals are preferably methyl, ethyl, propyl, methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1 ,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1- methylpentyl, if substituted also CHF₂, CF₃ or CH2OH etc. Preferably alkyl is understood in the context of this invention as C_1-6alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; preferably is C_1-6alkyl like methyl, ethyl, propyl, butyl, pentyl, or hexyl; more preferably is C₁-4alkyl like methyl, ethyl, propyl or butyl.

Alkenyl is understood as meaning unsaturated, linear or branched hydrocarbons, which may be unsubstituted or substituted once or several times. It encompasses groups like e.g. -CH=CH-CH₃. The alkenyl radicals are preferably vinyl (ethenyl), allyl (2-propenyl). Preferably in the context of this invention alkenyl is C₂-io-alkenyl or C_2-8-alkenyl like ethylene, propylene, butylene, pentylene, hexylene, heptylene or octylene; or is C_2-6- alkenyl like ethylene, propylene, butylene, pentylene, or hexylene; or is C_2-4-alkenyl, like ethylene, propylene, or butylenes. Alkynyl is understood as meaning unsaturated, linear or branched hydrocarbons, which may be unsubstituted or substituted once or several times. It encompasses groups like e.g. -C^C-CHa (1-propinyl). Preferably alkynyl in the context of this invention is C_2-10- alkynyl or C_2-6-alkynyl like ethyne, propyne, butyene, pentyne, hexyne, heptyne, or octyne; or is C_2-6-alkynyl like ethyne, propyne, butyene, pentyne, or hexyne; or is C_2-4- alkynyl like ethyne, propyne, butyene, pentyne, or hexyne. In connection with alkyl (also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl), alkenyl, alkynyl and O-alkyl - unless defined otherwise - the term substituted in the context of this invention is understood as meaning replacement of at least one hydrogen radical on a carbon atom by halogen (F, CI, Br, I), -NRcRc-, -SR_C, -S(0)R_c, -S(0)₂R_c, -OR_c, - C(0)ORc, -CN, -C(0)NRcRc\ haloalkyl, haloalkoxy or -OC_1-6 alkyl, being R_c represented by R₁₁, R12, R₁3, (being R₆- represented by R₁r, R12', R₁₃'; being R_c- represented by R₁₁,,, R₁2", R₁₃"; ) wherein R₁ to R₁r are as defined in the description, and wherein when different radicals R₁ to R₁₄,, are present simultaneously in Formula I they may be identical or different.

Most preferably in connection with alkyl (also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl), alkenyl, alkynyl or O-alkyl, substituted is understood in the context of this invention that any alkyl (also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl), alkenyl, alkynyl or O-alkyl which, if substituted, is substituted with one or more of halogen (F, CI, Br, I), -OR_c, -CN, -SR_c,-S(0)R_c, -S(0)₂R_c. haloalkyl, haloalkoxy, -NR_CR_C, or -OC_1-6alkyl, being R_c represented by R₁₁, R12, R₁₃, (being Rc- represented by R1₁-, R₁₂,, R₁3'; being Rcⁿ represented by R₁₁,, R₁2"i R₁₃";), wherein R₁ to R₁₄,,are as defined in the description, and wherein when different radicals R₁ to R₁₄,, are present simultaneously in Formula I, they may be identical or different.

More than one replacement on the same molecule and also on the same carbon atom is possible with the same or different substituents. This includes for example 3 hydrogens being replaced on the same C atom, as in the case of CF₃, or at different places of the same molecule, as in the case of e.g. -CH(OH)-CH=CH-CHCI₂.

In the context of this invention haloalkyl is understood as meaning an alkyl being substituted once or several times by a halogen (selected from F, CI, Br, I). It encompasses e.g. -CH₂CI, -CH₂F, -CHCI₂, -CHF₂, -CCI3, -CF₃ and -CH2-CHCI2. Preferably haloalkyl is understood in the context of this invention as haloge₁₁, substituted C₁-4-alkyl representing halogen substituted C1-, C2-, C3- or C4-alkyl. The halogen-substituted alkyl radicals are thus preferably methyl, ethyl, propyl, and butyl. Preferred examples include -CH₂CI, -CH₂F, -CHCI2, -CHF₂, and -CF₃.

In the context of this invention haloalkoxy is understood as meaning an -O-alkyl being substituted once or several times by a halogen (selected from F, CI, Br, I). It encompasses e.g. -OCH2CI, -OCH2F, -OCHCI2, -OCHF2, -OCCI_3l -OCF3 and - OCH₂-CHCI2. Preferably haloalkyl is understood in the context of this invention as halogen-substituted -OC_{1 -4}-alkyl representing halogen substituted C1-, C2-, C3- or C4- alkoxy. The halogen-substituted alkyl radicals are thus preferably O-methyl, O-ethyl, O-propyl, and O-butyl. Preferred examples include -OCH2CI, -OCH₂F, -OCHCI_2l - OCHF2, and -OCF3.

In the context of this invention cycloalkyl is understood as meaning saturated and unsaturated (but not aromatic) cyclic hydrocarbons (without a heteroatom in the ring), which can be unsubstituted or once or several times substituted. Furthermore, C3-4- cycloalkyl represents C3- or C4-cycloalkyl, C3-s-cycloalkyl represents C3-, C4- or C5- cycloalkyl, C_3§6-cycloalkyl represents C3-, C4-, C5- or C6-cycloalkyl, C3-7-cycloalkyl represents C3-, C4-, C5-, C6- or C7-cycloalkyl, C_3-8-cycloalkyl represents C3-, C4-, C5- , C6-, C7- or C8-cycloalkyl, C₄,5-cycloalkyl represents C4- or C5-cycloalkyl, C4-6- cycloalkyl represents C4-, C5- or C6-cycloalkyl, C₄,,₇-cycloalkyl represents C4-, C5-, C6- or C7-cycloalkyl, Cs_-6-cycloalkyl represents C5- or C6-cycloalkyl and Cs-7-cycloalkyl represents C5-, C6- or C7-cycloalkyl. Examples are cyclopropyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, and also adamantly. Preferably in the context of this invention cycloalkyl is C_3-8cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; or is C₃-7cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; or is C_3-6cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, especially cyclopentyl or cyclohexyl.

Aryl is understood as meaning 5 to 18 membered mono or polycyclic ring systems with at least one aromatic ring but without heteroatoms even in only one of the rings. Examples are phenyl, naphthyl, fluoranthenyl, fluorenyl, tetralinyl, indanyl, 9H-fluorenyl or anthracenyl radicals, which can be unsubstituted or once or several times substituted. Most preferably aryl is understood in the context of this invention as phenyl, naphthyl or anthracenyl, preferably is phenyl.

A heterocyclyl radical or group (also called heterocyclyl hereinafter) is understood as meaning 5 to 18 membered mono or poly heterocyclic ring systems, with at least one saturated or unsaturated ring which contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring. A heterocyclic group can also be substituted once or several times.

Examples include non-aromatic heterocyclyls such as tetrahydropyran, oxazepane, morpholine, piperidine, pyrrolidine as well as heteroaryls such as furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, thiazole, benzothiazole, indole, benzotriazole, carbazole and quinazoline.

Subgroups inside the heterocyclyls as understood herein include heteroaryls and non- aromatic heterocyclyls.

- the heteroaryl (being equivalent to heteroaromatic radicals or aromatic heterocyclyls) is an aromatic 5 to 18 membered mono or polycyclic heterocyclic ring system of one or more rings of which at least one aromatic 5 to 18 membered ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is an aromatic 5 to 18 membered mono or polycyclic heterocyclic ring system of one or two rings of which at least one aromatic ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzothiazole, indole, benzotriazole, carbazole, quinazoline, thiazole, imidazole, pyrazole, oxazole, thiophene and benzimidazole;

- the non-aromatic heterocyclyl is a 5 to 18 membered mono or polycyclic heterocyclic ring system of one or more rings of which at least one ring - with this (or these) ring(s) then not being aromatic - contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a 5 to 18 membered mono or polycyclic heterocyclic ring system of one or two rings of which one or both rings - with this one or two rings then not being aromatic - contain/s one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepam, pyrrolidine, piperidine, piperazine, tetrahydropyran, morpholine, indoline, oxopyrrolidine, benzodioxane, oxetane, especially is benzodioxane, morpholine, tetrahydropyran, piperidine, oxopyrrolidine, oxetane and pyrrolidine.

Preferably in the context of this invention heterocyclyl is defined as a 5 to 18 membered mono or polycyclic heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring. Preferably it is a 5 to 18 membered mono or polycyclic heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring.

Preferred examples of heterocyclyls include oxetane, oxazepane, pyrrolidine, imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1 ,2,5-thiadiazole, indole, benzotriazole, benzoxazole, oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline, especially is pyridine, pyrazine, indazole, benzodioxane, thiazole, benzothiazole, morpholine, tetrahydropyran, pyrazole, imidazole, piperidine, thiophene, indole, benzimidazole, pyrrolo[2,3b]pyridine, benzoxazole, oxopyrrolidine, pyrimidine, oxazepane, oxetane and pyrrolidine.

In the context of this invention oxopyrrolidine is understood as meaning pyrrolidin-2- one. In connection with aromatic heterocyclyls (heteroaryls), non-aromatic heterocyclyls, aryls and cycloalkyls, when a ring system falls within two or more of the above cycle definitions simultaneously, then the ring system is defined first as an aromatic heterocyclyl (heteroaryl) if at least one aromatic ring contains a heteroatom. If no aromatic ring contains a heteroatom, then the ring system is defined as a non-aromatic heterocyclyl if at least one non-aromatic ring contains a heteroatom. If no non-aromatic ring contains a heteroatom, then the ring system is defined as an aryl if it contains at least one aryl cycle. If no aryl is present, then the ring system is defined as a cycloalkyl if at least one non-aromatic cyclic hydrocarbon is present.

is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains a nitrogen and optionally one or more further heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains a nitrogen and optionally one or more further heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepam, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzimidazole, indazole, benzothiazole, benzodiazole, morpholine, indoline, triazole, isoxazole, pyrazole, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, quinolone, isoquinoline, tetrahydrothienopyridine, phthalazine, benzo-1 ,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, carbazole or thiazole.

In the context of this invention alkylaryl is understood as meaning an aryl group (see above) being connected to another atom through a C_1-6-alkyl (see above) which may be branched or linear and is unsubstituted or substituted once or several times. Preferably alkylaryl is understood as meaning an aryl group (see above) being connected to another atom through 1 to 4 (-CH₂-) groups. Most preferably alkylaryl is benzyl (i.e. -CH₂-phenyl). In the context of this invention alkylheterocyclyl is understood as meaning an heterocyclyl group (see above) being connected to another atom through a C_1-6-alkyl (see above) which may be branched or linear and is unsubstituted or substituted once or several times. Preferably alkylheterocyclyl is understood as meaning a heterocyclyl group (see above) being connected to another atom through 1 to 4 (-CH2-) groups. Most preferably alkylheterocyclyl is -CH₂-pyridine. In the context of this invention alkylcycloalkyl is understood as meaning an cycloalkyl group (see above) being connected to another atom through a C_1-6-alkyl (see above) which may be branched or linear and is unsubstituted or substituted once or several times. Preferably alkylcycloalkyl is understood as meaning a cycloalkyl group (see above) being connected to another atom through 1 to 4 (-CH2-) groups. Most preferably alkylcycloalkyl is -CHjrcyclopropyl.

Preferably, the aryl is a monocyclic aryl. More preferably the aryl is a 5, 6 or 7 membered monocyclic aryl. Even more preferably the aryl is a 5 or 6 membered monocyclic aryl.

Preferably, the heteroaryl is a monocyclic heteroaryl. More preferably the heteroaryl is a 5, 6 or 7 membered monocyclic heteroaryl. Even more preferably the heteroaryl is a 5 or 6 membered monocyclic heteroaryl.

Preferably, the non-aromatic heterocyclyl is a monocyclic non-aromatic heterocyclyl. More preferably the non-aromatic heterocyclyl is a 4, 5, 6 or 7 membered monocyclic non-aromatic heterocyclyl. Even more preferably the non-aromatic heterocyclyl is a 5 or 6 membered monocyclic non-aromatic heterocyclyl.

Preferably, the cycloalkyl is a monocyclic cycloalkyl. More preferably the cycloalkyl is a 3, 4, 5, 6, 7 or 8 membered monocyclic cycloalkyl. Even more preferably the cycloalkyl is a 3, 4, 5 or 6 membered monocyclic cycloalkyl. In connection with aryl (including alkyl-aryl), cycloalkyl (including alkyl-cycloalkyl), or heterocyclyl (including alkyl-heterocyclyl), substituted is understood - unless defined otherwise - as meaning substitution of the ring-system of the aryl or alkyl-aryl, cycloalkyl or alkyl-cycloalkyl; heterocyclyl or alkyl-heterocyclyl with one or more of halogen (F, CI, Br, I), -Rc ,-ORc, -CN, -NO2 , -NRcRc, -C(0)OR_c, NRcC(0)R«i , -C(0)NRcRc- , - NRcS(0)₂Rc- , =0, -OCH₂CH₂ORc, -NR_cC(0)NRc-Rc", -S(0)₂NRcRtf, -NRcS(0)₂NRcRc,,, haloalkyl, haloalkoxy, -SR_C, -S(0)R_c, -S(0)₂R_c or -C(CH₃)OR_c; NRcRc-, with R_c, Rc- and Rc- independently being either H or a saturated or unsaturated, linear or branched, substituted or unsubstituted C_1-6-alkyl; a saturated or unsaturated, linear or branched, substituted or unsubstituted C_1-6-alkyl; a saturated or unsaturated, linear or branched, substituted or unsubstituted -O-C_1-6-alkyl (alkoxy); a saturated or unsaturated, linear or branched, substituted or unsubstituted -S-C_1-6-alkyl; a saturated or unsaturated, linear or branched, substituted or unsubstituted -C(0)-C_1-6-alkyl-group; a saturated or unsaturated, linear or branched, substituted or unsubstituted -C(0)-0-C_1-6-alkyl-group; a substituted or unsubstituted aryl or alkyl-aryl; a substituted or unsubstituted cycloalkyl or alkyl-cycloalkyl; a substituted or unsubstituted heterocyclyl or alkyl-heterocyclyl, being Rc one of R₁₁, R₁₂ or R14, (being Rc- one of R₁₁-, R₁₂- orR₁₄,_; being R_c- one of R₁₁,, R₁2" or R₁₄,,;). wherein R₁ to R1₄,, are as defined in the description, and wherein when different radicals R₁ to R1₄,, are present simultaneously in Formula I they may be identical or different.

Most preferably in connection with aryl (including alkyl-aryl), cycloalkyl (including alkyl- cycloalkyl), or heterocyclyl (including alkyl-heterocyclyl), substituted is understood in the context of this invention that any aryl, cycloalkyl and heterocyclyl which is substituted is substituted (also in an alkylaryl, alkylcycloalkyl or alkylheterocyclyl) with one or more of halogen (F, CI, Br, I), -Rc ,-ORc, -CN , -N0₂ , -NR_CR_C- , NR_cC(0)Rc', - NR_cS(0)₂Rc , =0, haloalkyl, haloalkoxy, or -C(CH₃)OR_c; , being R_c one of R₁₁, R₁₂ or R₁₄, (being R_c- one of R₁₁-, R₁₂ or R₁₄,_; being R_c- one of R₁₁,, R₁₂- orR₁₄,,_:), wherein R₁ to R₁₄,,are as defined in the description, and wherein when different radicals R₁ to R₁₄-, are present simultaneously in Formula I they may be identical or different. Moreover, in connection with cycloalkyl (including alkyl-cycloalkyl), or heterocyclyl (including alkylheterocyclyl) namely non-aromatic heterocyclyl (including non-aromatic alkyl-heterocyclyl), substituted is also understood - unless defined otherwise - as meaning substitution of the ring-system of the cycloalkyl or alkyl-cycloalkyl; non- aromatic heterocyclyl or non aromatic alkyl-heterocyclyl with (leading to a spiro

structure) and/or =0.

Moreover, in connection with cycloalkyl (including alkyl-cycloalkyl), or heterocyclyl (including alkylheterocyclyl) namely non-aromatic heterocyclyl (including non-aromatic alkyl-heterocyclyl), substituted is also understood - unless defined otherwise - as meaning substitution of the ring-system of the cycloalkyl or alkyl-cycloalkyl; non- aromatic heterocyclyl or non aromatic alkyl-heterocyclyl is spirosubstituted or substituted with =0.

Moreover, in connection with cycloalkyl (including alkyl-cycloalkyl), or heterocyclyl (including alkylheterocyclyl) namely non-aromatic heterocyclyl (including non-aromatic alkyl-heterocyclyl), substituted is also understood - unless defined otherwise - as meaning substitution of the ring-system of the cycloalkyl or alkyl-cycloalkyl; non- aromatic heterocyclyl or non aromatic alkyl-heterocyclyl with =0. A ring system is a system consisting of at least one ring of connected atoms but including also systems in which two or more rings of connected atoms are joined with "joined'' meaning that the respective rings are sharing one (like a spiro structure), two or more atoms being a member or members of both joined rings.

The term "leaving group" means a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage. Leaving groups can be anions or neutral molecules. Common anionic leaving groups are halides such as CI—, Br-, and I-, and sulfonate esters, such as tosylate (TsO-) or mesylate. The term "salt" is to be understood as meaning any form of the active compound used according to the invention in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution. By this are also to be understood complexes of the active compound with other molecules and ions, in particular complexes via ionic interactions.

The term "physiologically acceptable salt" means in the context of this invention any salt that is physiologically tolerated (most of the time meaning not being toxic- especially not caused by the counter-ion) if used appropriately for a treatment especially if used on or applied to humans and/or mammals. These physiologically acceptable salts can be formed with cations or bases and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually a (deprotonated) acid - as an anion with at least one, preferably inorganic, cation which is physiologically tolerated - especially if used on humans and/or mammals. The salts of the alkali metals and alkaline earth metals are particularly preferred, and also those with NH₄, but in particular (mono)- or (di)sodium, (mono)- or (di)potassium, magnesium or calcium salts.

Physiologically acceptable salts can also be formed with anions or acids and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention as the cation with at least one anion which are physiologically tolerated - especially if used on humans and/or mammals. By this is understood in particular, in the context of this invention, the salt formed with a physiologically tolerated acid, that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if used on humans and/or mammals. Examples of physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.

The compounds of the invention may be present in crystalline form or in the form of free compounds like a free base or acid. Any compound that is a solvate of a compound according to the invention like a compound according to general formula I defined above is understood to be also covered by the scope of the invention. Methods of solvation are generally known within the art. Suitable solvates are pharmaceutically acceptable solvates. The term "solvate" according to this invention is to be understood as meaning any form of the active compound according to the invention in which this compound has attached to it via non- covalent binding another molecule (most likely a polar solvent). Especially preferred examples include hydrates and alcoholates, like methanolates or ethanolates.

Any compound that is a prodrug of a compound according to the invention like a compound according to general formula I defined above is understood to be also covered by the scope of the invention. The term "prodrug" is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention. Such derivatives would readily occur to those skilled in the art, and include, depending on the functional groups present in the molecule and without limitation, the following derivatives of the present compounds: esters, amino acid esters, phosphate esters, metal salts sulfonate esters, carbamates, and amides. Examples of well-known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found e.g. in Krogsgaard-Larsen et al. "Textbook of Drug design and Discovery" Taylor & Francis (April 2002).

Any compound that is an N-oxide of a compound according to the invention like a compound according to general formula I defined above is understood to be also covered by the scope of the invention.

Unless otherwise stated, the compounds of the invention are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by ¹³C- or ¹⁴C-enriched carbon or of a nitrogen by ¹⁵N-enriched nitrogen are within the scope of this invention. The compounds of formula (I) as well as their salts or solvates of the compounds are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. Purity levels for the drug substance are preferably above 50%, more preferably above 70%, most preferably above 90%. In a preferred embodiment it is above 95% of the compound of formula (I), or of its salts. This applies also to its solvates or prodrugs.

In a more particular embodiment the compound according to the invention of general Formula (I)

is a compound wherein

m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1 , 2 or 3; q is 0, 1 , 2 or 3; X is a bond or -0-; W is -CH- or nitrogen;

Y is a bond or -0-; R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₁ if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₁, -OR₁₁, -NO2, -NR₁₄,R₁₁,, NR₁₁C(0)R₁₁,, -NR₁₁S(0)₂R₁₁,, -S(0)₂NR₁₁R₁r, -NR₁₁C(0)NR₁rR_1r, -SR₁₁ , - S(0)R₁₁, -S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, -C(0)NR₁₁R₁r, -

OCH2CH2OR11, -NR₁₁S(0)₂NR₁rR₁r and -C(CH₃)₂OR₁₁;

wherein the alkyl, alkenyl or alkynyl in R₁, if substituted, is substituted with one or more substituent/s selected from -OR₁₁, halogen, -CN, haloalkyl, haloalkoxy and -

NR₁₁R₁₁,,; wherein R₁₁, R₁₁,,and R₁₁ - are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, wherein said cycloalkyl, aryl or heterocyclyl in R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₂, -OR12, -N0₂, -NR₁₂R₁₂-, - NR₁₂C(0)R₁₂-, -NR₁₂S(0)₂R₁₂', -S(0)₂NR₁₂R₁₂-, -NR₁₂C(0)NR₁₂ R₁₂ -, -SR_i2, -S(0)R₁₂,

-S(0)₂R₁₂, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁₂', -OCH₂CH₂OR₁₂, - NR₁₂S(0)₂NR₁₂ R₁₂- and -C(CH₃)₂OR₁₂; wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent/s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR₁₂R₁2,,; wherein R12, R₁₂- and R12 " are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl;

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-S alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R4 and R₄ are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 and R₄', may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R4 and R₄ may form together with the carbon atom to which they are attached a carbonyl group; R₄,, and FV-are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 " and R₄,,, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R₁₃'; wherein R₁₃ and R₁₃' are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl;

the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R14, -OR14, -NO2, -NRMRW, -NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, - NR₁₄C(0)NR₁₄-R₁₄,,, -SR,₄ , -S(0)R₁₄, S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄ , -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄R₁₄,, and -C(CH₃)₂OR₁₄;

wherein R₁₄, R_4', and R₁₄,,are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl;

These preferred compounds according to the invention are optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound wherein m is 0, 1 or 2; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound wherein r is 0, 1 or 2; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound wherein n is 0, 1 , 2 or 3; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In a further embodiment the compound according to the invention of general Formula (I) is a compound wherein q is 0, 1, 2 or 3; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound wherein

X is a bond or -0-; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a further embodiment the compound according to the invention of general f Formula (I) is a compound wherein

W is -CH- or nitrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In a further embodiment the compound according to the invention of general Formula (I) is a compound wherein

Y is a bond or -0-; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein

W is nitrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a further embodiment the compound according to the invention of general Formula (I) is a compound wherein R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In a further embodiment the compound according to the invention of general Formula (I) is a compound wherein R₁ is substituted or unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

R₂ is selected from substituted or unsubstituted C_1-6 alkyl and substituted or unsubstituted aryl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the according to the invention of general Formula (I) is a compound wherein R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the according to the invention of general Formula (I) is a compound wherein R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the according to the invention of general Formula (I) is a compound wherein

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)2R₅ and - C(0)NR₅R₅-; wherein R₅ and R₂, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; preferably R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; more preferably R₅ and R₅ are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl and substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another preferred embodiment of the compound according to the according to the invention of general Formula (I) is a compound wherein

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted alkylaryl, -C(0)R₅, -S(0)₂R₅ and -C(0)NR₅R₅; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted alkylaryl, -C(0)R₅, -S(0)₂R₅ and -C(0)NR₅R₅-; wherein R₅ and R_5' are independently selected from hydrogen, substituted or unsubstituted C₁_s alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; preferably R₅ and R are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; more preferably R₅ and R₅ are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl and substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein R₄ and R₄, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein R₄ and R₄, are both hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein R₄ and R₄, form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein

R4 and Reform together with the carbon atom to which they are attached a carbonyl group; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

R₄,, and R₄,,, are independently selected from hydrogen, substituted or unsubstituted C_1- 6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

R₄, and R - are independently selected from hydrogen and substituted or unsubstituted C_1-6 alkyl, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

R₄, and Ft*- form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein R₅ and R_5' are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl and substituted or unsubstituted aryl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I), (I^,), (la¹), (I²'), I³'). (I⁴'). (I⁵⁸'), (l^5b'), (I⁶⁸'), fl^6b'), (Γ') or (I⁸') is a compound wherein

Re andR₆ - in a compound of general formula (I²'), I³'), (I⁴'), (I⁵⁸"), (l^5b"), (l^6a") or (l^6bI) (or in a compound of general formula (I), (I^,), (la'), (I⁷') or (I⁸') - if R₁ is a pyridine - the substituent on the pyridine) are independently selected from halogen, -R₁₁, -OR₁₁, - N0₂, -NR₁₁R₁r, NRuC(0)R₁r. -NR₁₁S(0)₂R₁r, -S(0)₂NR₁₁R₁r, -NR₁₁C(0)NR₁rR₁r, - SR₁₁ , -S(0)R₁₁, -S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, -C(0)NR₁₁R_ir, - OCH₂CH₂OR₁₁, -NR₁₁S(0)₂NR₁₁ R₁₁" and -C(CH₃)₂OR₁₁; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I), (I^,), (la'), (I²'), I³'), (I⁴'), (I⁵⁸'), (l^5b'), (I*"), (l^eb'), (I⁷') or (I⁸') is a compound wherein

Re and R_e- in a compund of general formula (I²'), I³'). (I⁴'). fl⁵⁸'). (I^5b"). 0*") or (l^eb') (or in a compund of general formula (I), (I^,), (la'), (I⁷') or (l⁸') - if R₁ is a pyridine - the substituents on the pyridine) are both -R₁₁; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I), (I^,), (la ), (I²'), I³'), (I⁴'), (I⁵⁸'), (l^5b'), (I⁸⁸'), (l^8b'), (I⁷') or (I⁸') is a compound wherein

Re andR₆ - in a compund of general formula (I²'), I³'), (I⁴'), (I⁵⁸'), (l^5b"), (I⁸⁸") or (l^8b') (or in a compound of general formula (I), (I^,), (la'), (I⁷') or (I⁸') - if R₁ is a pyridine - the substituents on the pyridine) are both hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein R₁₁, R₁₁,,and R₁₁ - are independently selected from hydrogen, unsubstituted C_{1 -6} alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein R₁2, R₁₂,and R₁r are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein R₁3 and R₁r are independently selected from hydrogen, unsubstituted C₁-₆ alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I) is a compound wherein R₁₄, R₁₄, and R₁₄,, are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the compound according to the invention of general Formula (I), is a compound wherein m is 0, 1 or 2; and/or

r is 0, 1 or 2; and/or

n is 0, 1 , 2 or 3; and/or

q is 0, 1 , 2 or 3; and/or

X is a bond or-O-; and/or

Y is a bond or -0-;

and/or

W is -CH- or nitrogen; and/or

R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C3_-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphthyl , or anthracene; preferably is naphthyl and phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepane, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazoletetrahydropyran tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline; preferably the heterocyclyl is pyridine;

and/or

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C1-3 alkyl is isopropyl or isobutyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C_3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C« cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphthyl, or anthracene; preferably is naphthyl and phenyl; more preferably the aryl is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepane, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1 ,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline; and/or R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0>2R₅ and - C(0)NR₅R₅-; wherein the alkyl is C_1-6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; more preferably the alkyl is methyl; and/or the C1_-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C_1-6 alkyl is methyl or ethyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C3_-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphthyl , or anthracene; preferably is naphthyl and phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepane, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1 ,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline; and/or

R₄ and R₄, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; wherein the C1_-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-8 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or

R₄ and R₄, form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; wherein the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3.7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C_3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or

R4 and Reform together with the carbon atom to which they are attached a carbonyl group;

R₄, and f are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; wherein the C1-8 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; more preferably the C_1-6 alkyl is methyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or

R₄,, and f form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; wherein the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C34 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or

R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; wherein the C1-5 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C_1-6 alkyl is methyl or ethyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C_3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphthyl, or anthracene; preferably is naphthyl and phenyl; more preferably the aryl is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepan, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1 ,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline;

and/orR₆ and R₆ - are independently selected from halogen, -R₁₁, -OR₁₁, -N0₂, -NRHRH-, - NR₁₁C(0)R₁r, -NR₁₁S(0)₂R₁r, -S(0)₂NR₁₁R₁r, -NR₁₁C(0)NR₁₁ R₁r, -SR₁₁ , -S(0)R₁₁, - S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, -C(0)NR₁₁R₁r, -OCH₂CH₂ORu, - NR₁₁S(0)₂NR₁₁-R₁₁ - and -C(CH₃)₂OR₁₁; wherein

the alkyl is C_1-6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl;

and/or

R₁₁, R₁₁,,and R₁₁,, are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl; wherein the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;

and/or

R12, R₁2' and R₁ are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ; wherein

the C1_-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably, C_1-6 alkyl is ethyl ; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;

and/or R₁3 and R₁ are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl; wherein the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl;

and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-8 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or

R₁₄, R₁₄, and R1₄, are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; wherein the C1_-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C₃.₈ cycloalkyl like cyclopropyi, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyi, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C34 cycloalkyl like cyclopropyi, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphthyl , or anthracene; preferably is naphthyl and phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepane, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₁ as defined in any of the embodiments of the present invention, the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from Ca_-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphthyl , or anthracene; preferably is naphthyl and phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepane, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline; preferably the heterocyclyl is pyridine; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₂ as defined in any of the embodiments of the present invention, the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C_1-6 alkyl is isopropyl or isobutyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C_3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphthyl , or anthracene; preferably is naphthyl and phenyl; more preferably the aryl is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepane, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₆ as defined in any of the embodiments of the present invention, the alkyl is C_1-6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; more preferably the alkyl is methyl or ethyl; and/or the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C_1-6 alkyl is methyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C3_-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphthyl , or anthracene; preferably is naphthyl and phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepane, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₄ and R₄, as defined in any of the embodiments of the present invention, the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl

and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₄ and as defined in any of the embodiments of the present invention, the cycloalkyl is C_3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C3_-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R« and R₄, as defined in any of the embodiments of the present invention,

R4 and R₄, form together with the carbon atom to which they are attached a carbonyl group; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₄,, and R₄,,, as defined in any of the embodiments of the present invention, the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; more preferably the C_1-6 alkyl is methyl;

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₄, and R₄,,, as defined in any of the embodiments of the present invention, the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C_3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₅ and R5 as defined in any of the

embodiments of the present invention, the C1_-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyi, isopropyl, or 2-methylpropyl, more preferably the C_{1 -6} alkyl is methyl or ethyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C_3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C_3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphthyl , or anthracene; preferably is naphthyl and phenyl; more preferably the aryl is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepan, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₆ and R₆- as defined in any of the

embodiments of the present invention, the alkyl is C_1-6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl;

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₁₁, R₁r and R₁₁,, as defined in any of the embodiments of the present invention, the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C_2-8 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R1₂, R₁₂, and R12- as defined in any of the embodiments of the present invention,

the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, preferably, C_1-6 alkyl is ethyl ; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R₁₃ and R₁₃- as defined in any of the embodiments of the present invention,

the C_1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl;

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein in R14, R₁₄, and R1₄,, as defined in any of the embodiments of the present invention, the C1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C_2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C_2-6-alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C₃-₈ cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C34 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or the aryl is selected from phenyl, naphthyl , or anthracene; preferably is naphthyl and phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepane, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carbazole and quinazoline;

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein m is 0, 1 or 2; preferably m is 1 or 2; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein r is 0, 1 or 2; preferably r is 0 or 1 ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein n is 0, 1 , 2 or 3; preferably n is 0; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein q is 0, 1 , 2 or 3; preferably q is 0 or 1 ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein

Y is a bond or -0-; preferably, Y is a bond; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I) the compound is a compound, wherein Y is a bond or -0-; preferably, Y is -0-; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

W is -CH- or nitrogen; preferably W is nitrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

W is -CH- or nitrogen; preferably W is -CH-; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (I^,)

wherein m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1 , 2 or 3; q is 0, 1 , 2 or 3; X is a bond or -0-; W is -CH- or nitrogen; Y is a bond or -0-; R₁ is selected from substituted or unsubstituted C1_-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; R₃ is selected from hydrogen, substituted or unsubstituted C₁-β alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)2R₅ and - C(0)NR₅R₅ ; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; R₄ and R₄, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R and R ' may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R₄ and R₄, may form together with the carbon atom to which they are attached a carbonyl group;

R₄,, and R₄,,,are independently selected from hydrogen, substituted or unsubstituted C₁- 6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C₂._e alkynyl; alternatively, R₄,, and R₄,,, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

wherein m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1 , 2 or 3; q is 0, 1 , 2 or 3; X is a bond or -0-; W is -CH- or nitrogen; Y is a bond or -0-; R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₁ if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₁, -OR₁₁, -N0₂, -NR₁₁R₁r, - NR₁₁C(0)R₁₁,, -NR₁₁S(0)₂R₁₁,, -S(0)₂NR₁₁R₁r, -NR₁₁C(0)NR₁₁R₁r, -SR₁₁ , - S(0)R₁₁, -S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)ORu, -C(0)NR₁₁R₁r, - OCH₂CH₂OR11, -NR₁₁S(0)₂NR₁₁ R₁₁,, and -C(CH₃)₂OR₁₁;

wherein the alkyl, alkenyl or alkynyl in R₁, if substituted, is substituted with one or more substituent/s selected from -OR₁₁, halogen, -CN, haloalkyl, haloalkoxy and - NRuR₁₁,; wherein R₁₁, R₁₁,and R₁₁- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₂, -OR12, -N0₂, -NR₁₂R₁₂-, - NR₁₂C(0)R₁₂-, -NR₁₂S(0)₂R₁₂', -S(0)₂NR₁₂R₁₂-, -NR₁₂C(0)NR₁₂ R₁₂-, -SR₁₂, -S(0)R₁₂, S(0)₂R_12l -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁₂-, -OCH₂CH₂OR₁₂, -

NR₁₂S(0)₂NR₁₂R₁₂- and -C(CH₃)₂OR₁₂;

wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent/s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR₁₂R₁₂,,; wherein R₁₂, R₁₂' and R₁₂- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ; R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C₂-e alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)2R₅ and - C(0)NR₅R₅-; wherein R₅ and R_5' are independently selected from hydrogen, substituted or unsubstituted C1_-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R4 and R₄, are independently selected from hydrogen, substituted or unsubstituted C1_-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 and R4' may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R and R₄- may form together with the carbon atom to which they are attached a carbonyl group;

R₄,' and R₄, are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄, and R₄ " may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R_2l if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R₁₃-; wherein R₁₃ and R₁₃- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl;

the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent s selected from halogen, -R14, -OR14, -N0₂, -NR14R1₄,, -NR₁₄C(0)R₁₄', - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, - NR₁₄C(0)NR₁₄R₁₄,,, -SR14 , -S(0)R₁₄, -S(0)₂R,₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄,, -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄ R₁₄,, and -C(CH₃)₂OR₁₄;

wherein R₁₄, R₁₄, and R₁₄,,are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl;

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (la')

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3;

X is a bond or -0-;

W is -CH- or nitrogen; Y is a bond or -0-; R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; R2 is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

R3 is selected from hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R5 and - C(0)NR₅R₅-; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; R₄ and R₄, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 and R₄, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R₄ and R₄, may form together with the carbon atom to which they are attached a carbonyl group;

R₄,, and R4 ' " are independently selected from hydrogen, substituted or unsubstituted C₁- 6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R*- and R₄- may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (la')

(la),

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3; X is a bond or -0-; W is -CH- or nitrogen; Y is a bond or -0-; R₁ is selected from substituted or unsubstituted C_1-6alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₁ if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₁, -OR₁₁, -NO2, -NR₁₁R₁₁,, NR₁₁C(0)R₁r, -NR₁₁S(0)₂R₁₁,, -S(0)₂NR₁₁R₁₁,, -NR₁₁C(0)NR₁rR₁₁,, -SR₁₁ , - S(0)R₁₁, S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, -C(0)NR₁₁R₁r, - OCH2CH2OR11, -NR₁₁S(0)₂NR₁₁ R₁₁ " and C(CH₃)₂OR₁₁;

NR₁₁R₁₁,,; wherein R₁₁, R₁₁,,and R₁₁ - are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl;

R₂ is selected from hydrogen, substituted or unsubstitutedC_{1 -6} alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₂, -OR12, -NO2, -NR₁₂R₁₂-,

NR₁₂C(0)R₁₂', -NR₁₂S(0)₂R₁₂-, -S(0)₂NR₁₂R₁₂-, -NR₁₂C(0)NR₁₂ R₁₂,,, -SR₁₂, -S(0)R₁₂, S(0)₂R₁₂, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁₂', -OCH₂CH₂OR₁₂, - NR₁₂S(0)₂NR₁₂ R₁r and C(CH₃)₂OR₁₂;

wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent/s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR₁₂R₁₂,,; wherein R12, R₁₂- and R₁₂- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ;

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R5 and - C(0)NR₅R₅ ; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄ and R₄, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R and R4 may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R₄ and R₄, may form together with the carbon atom to which they are attached a carbonyl group;

R4" and R₄,,,are independently selected from hydrogen, substituted or unsubstituted C_1- 6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄,, and R₄- may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R₁3-; wherein R₁₃ and Rn- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C₂-e alkynyl;

the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R14, -OR14, -NO2, -NR14R14', NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, - NR₁₄C(0)NR₁₄ R₁₄,,, -SR14 , -S(0)R₁₄, S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄,, -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄ R₁₄,, and C(CH₃)₂OR₁₄;

wherein R14, R₁₄ and R₁₄-, are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl;

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (I²')

wherein m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1, 2 or 3; q is 0, 1 , 2 or 3;

X is a bond or-O-; W is -CH- or nitrogen; R2 is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; R3 is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅'; wherein R5 and R₅- are independently selected from hydrogen, substituted or unsubstituted C1_-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; R₄ and R₄, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 and R₄, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R₄ and R₄, may form together with the carbon atom to which they are attached a carbonyl group;

R₄,, and R4 -are independently selected from hydrogen, substituted or unsubstituted C₁- 6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄,, and R4 """ may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (I²')

wherein m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1 , 2 or 3; q is 0, 1 , 2 or 3;

X is a bond or -0-; W is -CH- or nitrogen;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₂, if substituted, is substituted with one or more substituent s selected from halogen, -R12, -OR12, -NO2, -NR12R12', - NR₁₂C(0)R₁2-, -NR₁₂S(0)₂R₁2-, -S(0)₂NR₁₂R₁2-, -NR₁₂C(0)NR₁₂R₁2,,, -SR₁₂, -S(0)R₁₂,

S(0)₂R₁2, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁₂-, -OCH₂CH₂OR₁₂, - NR₁2S(0)₂NR₁2'R₁2" and -C(CH₃)₂OR₁₂;

wherein the alkyl, alkenyl or alkynyl in R2, if substituted, is substituted with one or more substituent s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR12R12"; wherein R12, R12' and R₁ are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ;

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R5 and R_5' are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄ and R ' are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 and R₄, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R4 and R_4', may form together with the carbon atom to which they are attached a carbonyl group;

R₄, and R4 ' " are independently selected from hydrogen, substituted or unsubstituted C₁- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R_4', and R₄, - may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent s selected from halogen, -R₁₄, -OR14, -NO2, -NR₁₄R, ₁-r, -NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, - NR,₄C(0)NR₁₄,R₁₄,,, -SR_i4 , -S(0)R₁₄, -S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄,, -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄ R₁₄,, and -C(CH₃)₂OR₁₄;

wherein R14, R₁₄, and R14 · are independently selected from hydrogen, unsubstituted

C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (I³')

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3; X is a bond or -O W is -CH- or nitrogen;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R5 and - C(0)NR₅R₅-; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; R₄ and R₄, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R and R₄, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R₄ and R₄, may form together with the carbon atom to which they are attached a carbonyl group;

R₄, and R4 ' " are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄,, and R ·"" may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3;

X is a bond or -0-;

-CH- or nitrogen;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R12, -OR12, -NO2, -NR12R12', - NR₁₂C(0)R₁2-, -NR₁₂S(0)₂R₁2-, -S(0)₂NR₁₂R₁2-, -NR₁₂C(0)NR₁₂ R₁2", -SR12, -S(0)R₁₂,

-S(0)₂R₁2, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁₂-, -OCH2CH2OR12, - NR₁2S(0)₂NR₁2'R₁2" and -C(CH₃)₂OR₁2; wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR₁₂R₁2,,; wherein R12, R₁₂, and R₁r are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted Ci-β alkynyl ;

R3 is selected from hydrogen, substituted or unsubstituted O_-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅₎ -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄ and R4 are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 and R₄- may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R₄ and R₄, may form together with the carbon atom to which they are attached a carbonyl group; R4" and F are independently selected from hydrogen, substituted or unsubstituted C₁- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄,, and R4 ' " may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R_13'; wherein R₁₃ and R_13' are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl; the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R14, -OR14, -NO2, -NR14R14', -NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, - NR,4C(0)NR₁₄ R₁₄,,, -SR14 , -S(0)R₁₄, -S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄ , -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄ R₁₄,, and -C(CH₃)₂OR₁₄; wherein R₁₄, R₁₄, and R₁₄,,,are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl;

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (I⁴')

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3;

X is a bond or -0-;

W is -CH- or nitrogen;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R12, -OR12, -NO2, -NR12R12', - NR₁₂C(0)R₁2-, -NR₁₂S(0)2R₁₂,, -S(0)₂NR₁₂R₁2', -NR₁₂C(0)NR₁₂ R₁2", -SR₁₂, -S(0)R₁₂, -S(0)₂R₁2, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁2-, -OCH2CH2OR12, - NR₁₂S(0)₂NR₁2'R₁2" and -C(CH₃)20R₁₂; wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent/s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR12R12"; wherein R12, R₁₂, and R12" are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ;

R3 is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)2R₅ and - C(0)NR₅R5-; wherein R5 and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄, and R-nare independently selected from hydrogen, substituted or unsubstituted C_1- 6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄, and R₄,- may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R1 ; wherein R₁₃ and R₁₃- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl; the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₄, -OR14, -NO2, -NR14R14', -NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, - NR₁₄C(0)NR₁₄ R₁₄,,, -SR14 , -S(0)R₁₄, -S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄ , -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄R₁₄,, and -C(CH₃)₂OR₁₄;

wherein R₁₄, R₁₄ and R₁₄--are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

(Ι⁴').

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3; X is a bond or -0-; W is -CH- or nitrogen;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R_12> -OR₁₂, -N0_2l -NR12R12', - NR₁₂C(0)R,2-, -NR₁₂S(0)₂R₁2-, -S(0)₂NR₁2R₁₂-, -NR₁₂C(0)NR₁₂ R₁2,,, -SR12, -S(0)R₁₂, -S(0)₂R₁₂, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁₂-, -OCH₂CH₂OR₁₂, -

NR₁₂S(0)₂NR₁2-R₁2- and -C(CH₃)20R₁₂;

wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent/s selected from -OR₁₂, halogen, -CN, haloalkyl, haloalkoxy, - NR₁₂R₁₂,,; wherein R_12l R₁₂, and R₁₂- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ;

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C₂.₆ alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0) ₅, -S(0)2R₅ and - C(0)NR₅R₅-; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄, and R4 - " are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl; alternatively, R_4', and R ·"· may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R₁₃; wherein R₁₃ and R₁3- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl; the aryl, heterocyclyl or cycloalkyl other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent s selected from halogen, -R14, -OR14, -NO2, - NR₁₄R₁₄,, -NR₁₄C(0)R₁₄,, -NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, -NR₁₄C(0)NR₁₄ R₁₄,,, -SR14 , - S(0)R₁₄, -S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄,, - OCH2CH2OR14, -NR₁₄S(0)₂NR₁₄R₁₄,, and -C(CH₃)20R₁₄; wherein R₁₄, R₁₄ and R₁₄,,are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl;

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (I⁵⁸')

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3; X is a bond or -0-;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted d-o alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R5, -S(0>2R₅ and - C(0)NR₅R₅-; wherein R₅ and R_5' are independently selected from hydrogen, substituted or unsubstituted C1-3 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R4 - and R₄,,, are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄,, and R* "·" may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3; X is a bond or -0-;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R12, -OR₁₂, -N0₂, -NR12R12', NR₁₂C(0)R₁2-, -NR₁2S(0)₂R₁2-, -S(0)₂NR₁₂R₁2-, -NR₁₂C(0)NR₁₂ R₁2", -SR12, -S(0)R₁₂, S(0)₂R₁2, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁₂-, -OCH2CH2OR12, - NR₁₂S(0)2lMR₁₂'R₁2" and -C(CH3)₂OR₁₂; wherein the alkyl, alkenyl or alkynyl in R2, if substituted, is substituted with one or more substituent/s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR12R12"; wherein R12, R₁₂, and R₁₂- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ;

R₅ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R5 and - C(0)NR₅R₅'; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄,, and R₄,,, are independently selected from hydrogen, substituted or unsubstituted O. β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄,, and R₄ " may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R₁₃ ; wherein R₁₃ and R₁₃' are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl; the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R14, -OR™, -NO2, -NRMRM-, -NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, - NR₁₄C(0)NR₁₄R₁₄,,, -SR14 , -S(0)R₁₄, -S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄,, -OCH2CH2OR14, -NR₁₄S(0)₂NR₁₄ R₁₄,, and -C(CH₃)₂OR₁₄;

wherein R₁₄, R₁₄,,and R₁₄-, are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl;

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (l^5b')

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3; X is a bond or -0-;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C2_-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R₅ and R_5' are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

Re and R₄,,,are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 "" and R₄, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

wherein

R2 is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R12, -OR12, -NO2, -NR12R17, -

NR₁₂C(0)R₁2-, -NR₁₂S(0)₂R₁2-, -S(0)₂NR₁₂R₁z, -NR₁₂C(0)NR₁₂R₁2", -SR12, -S(0)R₁₂, -S(0)₂R₁2, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁₂-, -OCH₂CH₂OR₁₂, - NR₁2S(0)₂NR₁2-R₁2" and -C(CH₃)₂OR₁2;

wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent/s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR12R12"; wherein R12, R₁2- and R12- are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-3 alkynyl ;

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R₅ and R₅, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R4 " and R4 ' " are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 ' " and R4 ' " may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R₁₃ ; wherein R₁₃ and R₁3 are independently selected from hydrogen, unsubstituted C14 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-8 alkynyl;

the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₄, -OR14, -N0₂, -NR14R1₄,, -NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, - NR₁₄C(0)NR₁₄ R₁₄,,, -SR14 , -S(0)R₁₄, S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄,, -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄R₁₄,, and -C(CH₃)20R₁₄;

wherein R14, R₁₄ and R₁₄ " are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (l^6a')

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3; R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)2R₅ and - C(0)NR₅R₅-; wherein R5 and R_5' are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄, and R₄ - are independently selected from hydrogen, substituted or unsubstituted C₁- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 "- and Rc- may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (I⁶⁸')

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₂, -OR₁₂, -N0_2l -NR₁₂R₁₂-, - NR₁₂C(0)R₁2', -NR₁₂S(0)₂R₁2-, -S(0)₂NR₁₂R₁₂-, -NR₁₂C(0)NR₁₂ R₁₂-, -SR₁₂, -S(0)R₁₂, S(0)₂R₁₂, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁₂-, -OCH₂CH₂OR₁₂, - NR₁2S(0)₂NR₁2'R₁2" and -C(CH₃)₂OR₁₂; wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent/s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR12R12"; wherein R12, R17 and R₁ are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ;

R3 is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅; wherein R5 and R₅- are independently selected from hydrogen, substituted or unsubstituted C1-5 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

Re and Re- are independently selected from hydrogen, substituted or unsubstituted C₁- 6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, Re and Re- may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R₁₃'; wherein R₁₃ and R₁ are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl; the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R14, -OR14, -NO2, -NR₁₄R₁₄-, -NR₁₄C(0)R₁₄-, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,. - NR₁₄C(0)NR₁₄R₁₄,,, -SR₁₄ , -S(0)R_14l S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR_14l -C(0)NR₁₄R₁₄-, -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄-R₁₄- and -C(CH₃)₂OR₁₄;

wherein R₁₄, R₁₄ and R₁₄,,are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (l^6b')

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3; R2 is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

R3 is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R5 and R_5' are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄, and R₄,-are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, Re and R4 - may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (l^6b')

wherein m is 0, 1 or 2; r is 0, 1 or 2; q is 0, 1 , 2 or 3;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R12, -OR12, -NO2, -NR12R12 , - NR₁₂C(0)R₁2-, -NR₁₂S(0)₂R₁2-, -S(0)2NR₁₂R₁₂', -NR₁2C(0)NR₁₂ R₁2", -SR12, -S(0)R₁₂, -S(0)₂R₁2, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁2-, -OCH2CH2OR12, - NR₁₂S(0)₂NR₁2R₁2" and -C(CH₃)20R₁₂; wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent/s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR12R12"; wherein R12, R₁₂, and R₁r are independently selected from hydrogen, unsubstituted

C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ;

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R5 and R₅- are independently selected from hydrogen, substituted or unsubstituted C1_-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄,, and R4 ' " are independently selected from hydrogen, substituted or unsubstituted C₁- 6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄, and RA- may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R₁₃-; wherein R₁₃ and R₁ are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-8 alkynyl; the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R_14> -OR14, -NO2, -NRHRM-, -NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, - NR₁₄C(0)NR₁₄R₁₄,,, -SR,₄ , -S(0)R₁₄, S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄,, -OCH₂CH₂OR₁₄, -NR₁₄S, (0)₂NR₁₄ R₁₄,, and -C(CH₃)₂OR₁₄;

wherein R₁₄, R₁₄,,and R^-are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (I⁷')

wherein m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1 , 2 or 3; q is 0, 1 , 2 or 3; X is a bond or -0-; W is -CH- or nitrogen; Y is a bond or -0-; R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅'; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C2-0 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; R₄,, and f¾ -are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄,, and R₄,, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

wherein m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1, 2 or 3; q is 0, 1 , 2 or 3;

X is a bond or -0-;

W is -CH- or nitrogen; Y is a bond or-O-; R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₁ if substituted, is substituted with one or more substituent s selected from halogen, -R₁₁, -OR₁₁, -NO2, -NR₁₁R₁₁,, - NR₁₁C(0)R₁r, -NR₁,S(0)₂R₁r, -S(0)₂NR₁₁R₁r, -NR₁,C(0)NR₁₁ R₁r, -SR₁₁ , - S(0)R₁₁, -S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, -C(0)NR₁₁R₁r, - OCH2CH2OR11, -NR₁₁S(0)₂NR₁rR₁ and -C(CH₃)₂OR₁₁;

wherein the alkyl, alkenyl or alkynyl in R₁, if substituted, is substituted with one or more substituent s selected from -OR₁₁, halogen, -CN, haloalkyl, haloalkoxy and - NR11R11"; wherein R₁₁, R₁₁,,and R₁₁, are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl;

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R12, -OR12, -N0₂, -NR12R12', - NR₁₂C(0)R₁2-, -NR₁₂S(0)₂R₁₂-, -S(0)₂NR₁₂R₁₂-, -NR₁₂C(0)NR₁₂ R₁₂,,, -SR₁₂, -S(0)R₁₂, -S(0)₂R_12l -CN, haloalkyl, haloalkoxy, -C(0)OR_12l -C(0)NR₁₂R₁₂-, -OCH₂CH₂OR₁₂, - NR₁₂S(0)₂NR₁2 R₁2" and -C(CH₃)₂OR₁₂;

wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR₁₂R₁₂-; wherein R12, R12 and R₁₂- are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_3-6 alkynyl ;

R3 is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R₅ and R₂, are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄,, and Re- are independently selected from hydrogen, substituted or unsubstituted C_1- 6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, RA- and R₄ """ may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R_2| if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NRISRIT; wherein R₁₃ and R₁3- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl;

the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R14, -OR14, -N0₂, -NR14R1₄,, -NR₁₄C(0)R₁₄', - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,. - NR₁₄C(0)NR₁₄R₁₄,,, -SR₁₄ , -S(0)R₁₄, S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄,, -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄-R₁₄,, and -C(CH₃)₂OR₁₄;

wherein R₁₄, R₁band R₁₄-, are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl;

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (l⁸')

wherein m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1 , 2 or 3; q is 0, 1 , 2 or 3;

X is a bond or -0-; W is -CH- or nitrogen; R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; R2 is selected from hydrogen, substituted or unsubstituted C1_-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

R3 is selected from hydrogen, substituted or unsubstituted C1-5 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R₅ and R₅- are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R4" and R4 - are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄,, and R₄,, may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (I⁸')

(I⁸),

wherein m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1 , 2 or 3; q is 0, 1 , 2 or 3; X is a bond or -0-; W is -CH- or nitrogen; R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-8 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₁ if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₁, -OR₁₁, -N0₂, -NR₁₁R₁r, -

NR,iC(0)R₁r, -NR,,S(0)2R₁r, -S(0)₂NR₁₁R₁₁., -NR₁₁C(0)NR₁₁ R₁₁,,, -SR₁₁ , - S(0)R₁₁, -S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, -C(0)NR₁₁R₁r, - OCH₂CH₂OR₁₁, -NR₁₁S(0)₂NR₁₁ R_11" and -C(CH₃)₂OR₁₁;

wherein the alkyl, alkenyl or alkynyl in R₁, if substituted, is substituted with one or more substituent/s selected from -OR₁₁, halogen, -CN, haloalkyl, haloalkoxy and - NR₁₁R₁₁,,; wherein R₁₁, R₁₁,,and R₁₁,,are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C₂-5 alkynyl; R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₂, -OR12, -N0₂, -NR12R12', - NR₁₂C(0)R_1?, -NR₁₂S(0)₂R₁2-, -S(0)₂NR₁₂R₁z, -NR₁₂C(0)NR₁₂R₁₂,,, -SR₁₂, -S(0)R₁₂, -S(0)₂R₁2, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁ , -OCH₂CH₂OR₁₂, - NR₁₂S(0)₂NR₁₂R₁₂" and -C(CH₃)₂OR₁₂;

wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent s selected from -OR₁₂, halogen, -CN, haloalkyl, haloalkoxy, - NR₁₂R₁₂,,; wherein R₁₂, R₁₂, and R17- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ;

R₃ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R_5l -S(0)₂R₅ and - C(0)NR₅R₅-; wherein R₅ and R_5' are independently selected from hydrogen, substituted or unsubstituted C1-3 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; R₄,, and R-i -are independently selected from hydrogen, substituted or unsubstituted C₁- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R₄,, and R4 " may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl;

the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R₁₃'; wherein R₁₃ and R₁3- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C_2-6 alkynyl;

the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R14, -OR14, -NO2, -NRMRW, -NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, - NR₁₄C(0)NR₁₄ R₁₄,,, -SR14 , -S(0)R₁₄, -S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄,, -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄ R₁₄,, and -C(CH₃)₂OR₁₄;

wherein R14, R₁₄,,and R₁₄,,are independently selected from hydrogen, unsubstituted C1_-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl;

optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another preferred embodiment of the invention according to general Formula (I), the compound is a compound of Formula (I^,),

a compound of Formula (I²')

a compound of Formula (I⁴')

compound of Formula (I⁵⁸')

a compound of Formula (l^5b')

a compound of Formula (l^6a") R₃

a compound of Formula (l^eb')

R₃

(l^eb')

whereinR₆ andR₆- are independently selected from halogen, -R₁₁, -OR₁₁, -N0₂, -NR₁₁R₁₁", -NR₁₁C(0)R₁₁,, -NR,iS(0)₂R₁r, -S(0)₂NR₁₁R₁r, -NR₁₁C(0)NR₁₁ R₁r, -SR11 , -S(0)R₁₁, -S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, - C(0)NR₁₁R₁r, -OCH2CH2OR11, -NR₁₁S(0)₂NR₁₁ R₁₁ · and -C(CH₃)₂OR₁₁; and R₁₁, R₁₁,,and R₁₁, are independently selected from hydrogen, unsubstituted C1-8 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl. optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a preferred embodiment m is 1 or 2.

In a preferred embodiment r is 0 or 1.

In a preferred embodiment n is 1.

In a preferred embodiment n is 0.

In a preferred embodiment q is 0 or 1.

In a preferred embodiment

Y is a bond.

In a preferred embodiment

Y is -0-. In a preferred embodiment X is a bond or -0-. In a preferred embodiment W is nitrogen. In a preferred embodiment W is -CH-.

In a preferred embodiment, R₁ is a substituted or unsubstituted pyridine, preferably unsubstituted pyridine. In a preferred embodiment

R₂ is substituted or unsubstituted group selected from isopropyl, isobutyl and phenyl, more preferably an unsubstituted group selected from isopropyl, isobutyl and phenyl.

In a preferred embodiment

R₃ is hydrogen or a substituted or unsubstituted group selected from methyl, 1- propiopyl, benzyl, acetyl, benzoyl, -S(0)2-methyl and -C(0)NH-methyl; preferably hydrogen or an unsubstituted group selected from methyl, 1 -propiopyl, benzyl, acetyl, benzoyl, -S(0)2-methyl and -C(0)NH-methyl.

In a preferred embodiment R3 is hydrogen or a substituted or unsubstituted group selected from methyl, ethyl, 1- propiopyl, benzyl, acetyl, benzoyl, -S(0)2-methyl and -C(0)NH-methyl; preferably hydrogen or an unsubstituted group selected from methyl, 1 -propiopyl, benzyl, acetyl, benzoyl, -S(0)2-methyl and -C(0)NH-methyl. In a preferred embodiment R is hydrogen. In a preferred embodiment R4' is hydrogen. In a preferred embodiment

R₄, is hydrogen. In a preferred embodiment R4 - is hydrogen. In a preferred embodiment

R₄, is substituted or unsubstituted methyl, preferably unsubstituted methyl. In a preferred embodiment

R4 ' " is substituted or unsubstituted methyl, preferably unsubstituted methyl. In a preferred embodiment R₄ and R₄, are both hydrogen. In a preferred embodiment

R₄, and R4 ' " are both hydrogen. In a preferred embodiment

R₄, and R4 ' " are both substituted or unsubstituted methyl; preferably R₄, and R4 ' " are both unsubstituted methyl. In a preferred embodiment

R₄ and R₄, are both hydrogen, while R₄, and R4 ' " are both substituted or unsubstituted methyl; preferably while R4 ' " and R₄, are both unsubstituted methyl. In a preferred embodiment

R4, R ', ₄,, and R4 " are all hydrogen.

In a preferred embodiment

R4 and Reform together with the carbon atom to which they are attached a carbonyl group.

In a preferred embodiment

R4 and Reform together with the carbon atom to which they are attached a carbonyl group, while Re and R4 ' "" are both hydrogen.

In a preferred embodiment R₅ is hydrogen or a substituted or unsubstituted group selected from methyl, ethyl and phenyl; preferably hydrogen or an unsubstituted group selected from methyl, ethyl and phenyl.

In a preferred embodiment R₅- is substituted or unsubstituted methyl, preferably unsubstituted methyl. In a preferred embodiment R₅ is hydrogen or a substituted or unsubstituted group selected from methyl, ethyl and phenyl; preferably hydrogen or an unsubstituted group selected from methyl, ethyl and phenyl, while R₅- is substituted or unsubstituted methyl, preferably unsubstituted methyl.

In a preferred embodimentR₆ andR₆ - are both hydrogen.

In a preferred embodiment

R11 is hydrogen. In a preferred embodiment R₁2 is hydrogen. In a preferred embodiment R₁₄ is hydrogen.

In a preferred further embodiment, the compounds of the general Formula (I) are selected from

In a preferred embodiment of the compound according to the invention of general Formula (I), R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in R₁ if substituted, is substituted with one or more substituent s selected from halogen, -R₁₁, -OR₁₁, -N0₂, -NR₁₁R₁₁,, - NR₁₁C(0)R₁r, -NR₁₁S(0)₂R₁r, -S(0)₂NR₁₁R₁r, -NR₁₁C(0)NR₁₁ R₁r, -SR₁₁ , - S(0)R₁₁, S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, -C(0)NR₁₁R₁r, - OCH2CH2O R₁₁, -NR₁₁S(0)₂NR₁rR₁r and -C(CH₃)₂OR₁₁;

NR11R11"; wherein R₁₁, R₁₁,,and R₁₁, are independently selected from hydrogen, unsubstituted

C1_-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In another embodiment of the invention the compound of general Formula (I),

R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein said cycloalkyl, aryl or heterocyclyl in f¾, if substituted, is substituted with one or more substituent/s selected from halogen, -R12, -OR12, -NO2, -NR12R12, - NR₁₂C(0)R₁2-, -NR₁₂S(0)₂R₁2-, -S(0)₂NR₁2R₁2-, -NR₁₂C(0)NR₁₂ R₁2", -SR12, -S(0)R₁₂, S(0)₂R₁2, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁₂ , -OCH₂CH₂OR₁₂, - NR₁2S(0)₂NR₁2-R₁2' and -C(CH₃)₂OR₁₂;

wherein the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, - NR₁₂R₁2,,; wherein R12, R₁₂ and R₁₂- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another embodiment of the invention the compound of general Formula (I), the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R₁₃ ; wherein R₁₃ and R₁3- are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, and unsubstituted C₂.₆ alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In another embodiment of the invention the compound of general Formula (I), the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R₂, if substituted, is substituted with one or more substituent/s selected from halogen, -R14, -OR14, -NO2, -NR14R1₄,, -NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR,4R₁₄,, - NR₁₄C(0)NR₁₄ R₁₄,·,, -SR14 , -S(0)R₁₄, -S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₄, -C(0)NR₁₄R₁₄,, -OCH₂CH₂OR₁₄, -NR₁₄S(0)₂NR₁₄-R₁₄, and -C(CH₃)₂OR₁₄; wherein R14, R₁band R₁₄-, are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl, unsubstituted C_2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a preferred embodiment of the compound according to the invention of general Formula (I) and in relation to R₁ of any of the embodiments of the present invention, the cycloalkyl, aryl or heterocyclyl in R₁ if substituted, is substituted with one or more substituent/s selected from halogen, -R₁₁, -OR₁₁, -N0₂, -NR₁₁R₁₁ , -NR₁₁C(0)R₁₄,,, - NR₁₁S(0)₂R₁r, -S(0)₂NR₁₁R₁r, -NR₁₁C(0)NR₁₁ R₁r, -SR₁₁ , -S(0)R₁₁, -S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, -C(0)NR₁₁R₁r, -OCH₂CH₂OR₁₁, -NR₁₁S(0)₂NR₁₁ R_1r and -C(CH₃)₂OR₁₁; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a preferred embodiment of the compound according to the invention of general Formula (I) and in relation to R₁ of any of the embodiments of the present invention, the alkyl, alkenyl or alkynyl in R₁, if substituted, is substituted with one or more substituent s selected from -OR₁₁, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₁R₁₁,; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a preferred embodiment of the compound according to the invention of general Formula (I) and in relation to R∑ of any of the embodiments of the present invention, the cycloalkyl, aryl or heterocyclyl in R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R12, -OR12, -NO2, -NR12R17, -NR₁₂C(0)R₁₂', -

NR₁₂S(0)₂R₁₂-, -S(0)₂NR₁₂R₁2-, -NR₁₂C(0)NR₁2-R₁2,,, -SR12, -S(0)R₁₂, -S(0)₂R₁₂, - CN, haloalkyl, haloalkoxy, -C(0)OR₁₂, -C(0)NR₁₂R₁2-, -OCH2CH2OR12, - NR₁₂S(0)₂NR₁2'R₁2" and -C(CH₃)20R₁₂; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof. In a preferred embodiment of the compound according to the invention of general Formula (I) and in relation to R₂ of any of the embodiments of the present invention, the alkyl, alkenyl or alkynyl in R₂, if substituted, is substituted with one or more substituent/s selected from -OR12, halogen, -CN, haloalkyl, haloalkoxy, -NR12R12"; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a preferred embodiment of the compound according to the invention of general Formula (I) and in relation to alkyls other than those defined in R₁ or R₂ of any of the embodiments of the present invention, the alkyl, alkenyl or alkynyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from -OR₁₃, halogen, -CN, haloalkyl, haloalkoxy and -NR₁₃R1 ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In a preferred embodiment of the compound according to the invention of general Formula (I) and in relation to the cycloalkyl, aryl or heterocyclyl other than those defined in R₁ or R2 of any of the embodiments of the present invention, the aryl, heterocyclyl or cycloalkyl, also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl, other than those defined in R₁ or R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R14, -OR , -NO2, -NRMRW, -NR₁₄C(0)R₁₄,, - NR₁₄S(0)₂R₁₄,, -S(0)₂NR₁₄R₁₄,, -NR₁₄C(0)NR₁₄R₁₄,,, -SR14 , -S(0)R₁₄, -S(0)₂R₁₄, -CN, haloalkyl, haloalkoxy, -C(0)OR₁ , -C(0)NR₁₄R₁₄\ -OCH2CH2OR14, -NR₁₄S(0)₂NR₁₄ R₁₄,, and -C(CH₃)₂OR₁₄; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

In an embodiment of the compound according to the invention of general Formula (I), the halogen is fluorine, chlorine, iodine or bromine; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

As this invention is aimed at providing a compound or a chemically related series of compounds which act as dual ligands of the σ₁ receptor and the μ-opioid receptor it is a very preferred embodiment in which the compounds are selected which act as dual ligands of the σ₁ receptor and the μ-opioid receptor and especially compounds which have a binding expressed as K, which is preferably < 1000 nM for both receptors, more preferably < 500 nM, even more preferably < 100 nM.

In the following the phrase "compound of the invention" is used. This is to be understood as any compound according to the invention as described above according to general Formulae (I), (I^,), (la'), (I²'), (I³¹), (I⁴'), (l^5a'), (l^5b'), (I*"). (I^eb"). (I⁷'). or (I⁸').

The compounds of the invention represented by the above described Formula (I) may include enantiomers depending on the presence of chiral centres or isomers depending on the presence of multiple bonds (e.g. Z, E). The single isomers, enantiomers or diastereoisomers and mixtures thereof fall within the scope of the present invention. In general the processes are described below in the experimental part. The starting materials are commercially available or can be prepared by conventional methods. A preferred aspect of the invention is also a process for the production of a compound according to Formula (I), following scheme 1.

A preferred aspect of the invention is a process for the production of a compound according to Formula (I), wherein R₁, R2, R3, R4, ₄,, R₄,-, R4 ' " , R₅, R₅-, m, n, q, r, X, Y and W are as defined in the description, following scheme 1. For the sake of clarity the expression "a compound according to Formula (I), wherein e.g. R₁, etc. are as defined in the description" would (just like the expression "a compound of Formula (I) as defined in any one of claims e.g. 1 to 10" found in the claims) refer to "a compound according to Formula (I)", wherein the definitions of the respective substituents R₁ etc. (also from the cited claims) are applied. In addition, this would also mean, though (especially in regards to the claims) that also one or more disclaimers defined in the description (or used in any of the cited claims like e.g. claim 1) would be applicable to define the respective compound. Thus, a disclaimer found in e.g. claim 1 would be also used to define the compound "of Formula (I) as defined in any one of the corresponding related claims e.g. 1 to 10".

A process is described in Scheme 1 for the preparation of compounds of general formula I, wherein R₁, R₂, R3, R4, ¾·, R₄,, R₄,,,, m, n, q, r, W, X and Y have the meanings defined in the description and Z is chlorine or bromine.

A preferred embodiment of the invention is a process for the production of a compound according to Formula (I),

(I). wherein compounds of general formula IVb

are treated with a lithium salt in situ generated from compounds of general formula V

with nBuLi, in a suitable solvent, at a suitable temperature, and subsequently hydrolized to ketone, wherein Z is chlorine or bromine, P is Q, and Q is

and wherein R₁ , R₂, Ra, R₄, R₄,, R4 ' ", R4 -, m, n, q, r, W, X and Y have the meanings defined in the description. A preferred embodiment of the invention is a process for the production of a compound according to Formula (I),

(I). wherein compounds of general formula VIII

are reacted with a compound of formula Vila

in a suitable solvent, in the presence of a base, at a suitable temperature, preferably in a microwave reactor, wherein R₁, R₂, R₂, R*, R₄, , R₄,,, Re, m, n, q, r, X, W and Y have the meanings defined in the description. A preferred embodiment of the invention is a process for the production of a compound according to Formula (I),

(I), wherein compounds of general formula VIII

are reacted with a compound of formula Vllb

in the presence of a reductive reagent, in a suitable solvent, at a suitable temperature, preferably in a microwave reactor, wherein R₁, R2, R3, R4, R4', R4'', R4''', m, n, q, r, X, W and Y have the meanings defined in the description. A preferred embodiment of the invention is a process for the production of a compound according to Formula (I),

wherein compounds of general formula IVb

with nBuLi, in a suitable solvent, at a suitable temperature, and subsequently hydrolized to ketone compounds of formula (I), or

wherein compounds of general formula VIII

are reacted with a compound of formula Vila

in a suitable solvent, in the presence of a base, at a suitable temperature, preferably in a microwave reactor, or wherein compounds of general formula VIII

are reacted with a compound of formula Vllb

in the presence of a reductive reagent, in a suitable solvent, at a suitable temperature, preferably in a microwave reactor, wherein Z is chlorine or bromine, P is Q, and Q is

wherein R₁, R₂, Ra, Ro, R₄,, R₄,, R₄,-, m, n, q, r, X, W and Y have the meanings defined in the description.

A preferred embodiment of the invention is a process, wherein n is 0 and W is nitrogen, for the production of a compound of Formula (IVa) or (IVb) starting from a compound of Formula (II),

wherein P is a protecting group PG such as Boc (tert-butoxycarbonyl), Teoc (2- (trimethylsilyl)ethoxycarbonyl) or benzyl, or P is Q, and Q is

and wherein R2, R3, R4, R4', R-j", Rt-, m, n, q, r, X and Y have the meanings defined in the description. A preferred embodiment of the invention is a process, for the production of a compound of Formula (VI) starting from a compound of Formula (IVa),

wherein P is a protecting group PG such as Boc (tert-butoxycarbonyl), Teoc (2- (trimethylsilyl)ethoxycarbonyl) or benzyl, Z is chlorine or bromine, and wherein R₁, R3, R4, R4', R₄,, R₄,,,, m, n, r and Y have the meanings defined in the description.

A preferred embodiment of the invention is a process for the production of a compound of Formula (VIII) starting from a compound of Formula (VI),

wherein P is a protecting group PG such as Boc (tert-butoxycarbonyl), Teoc (2- (trimethylsilyl)ethoxycarbonyl) or benzyl, and wherein R₁, R3, R4, R4; Rr, R₄", m, n, r and W have the meanings defined in the description.

A preferred embodiment of the invention is a process for the production of a compound of Formula (I) starting from a compound of Formula (VIII),

wherein P is Q, Q is

L is a leaving group such as halogen, mesylate, tosylate or inflate, and wherein R₁, R2, R₃, R4, R4 , R₄,,, R4 ", m, n, q, r, X, Y and W have the meanings defined in the description. In another particular embodiment a compound of Formula (II),

wherein R3, R4, R₄,, Re, m, r and Y have the meanings defined in the description, is used for the preparation of a compound of Formula (I).

In another particular embodiment a compound of Formula (Ilia),

wherein P is a protecting group PG such as Boc (tert-butoxycarbonyl), Teoc (2- (trimethylsilyl)ethoxycarbonyl) or benzyl, and W has the meaning defined in the description, is used for the preparation of a compound of Formula (I).

In another particular embodiment a compound of Formula (1Mb),

wherein P is Q and Q is

has the meaning defined in the description, is used for the preparation of a compound of Formula (I).

In another particular embodiment a compound of Formula (IVa),

wherein P is a protecting group PG such as Boc (tert-butoxycarbonyl), Teoc (2- (trimethylsilyl)ethoxycarbonyl) or benzyl, and wherein R3, R₄, R₄,, Re, Rv; m, r, n, W and Y have the meanings defined in the description, is used for the preparation of a compound of Formula (I).

In another particular embodiment a compound of Formula (IVb),

wherein P is Q and Q is

Z , and wherein R3, f , R₄,. R₄,,, R₄,-, m, r, n, W and Y have the meanings defined in the description, is used for the preparation of a compound of Formula (I).

In another particular embodiment a compound of Formula (V),

wherein Z is chlorine or bromine, and wherein R₁ has the meanings defined in the description is used for the preparation of a compound of Formula (I).

In another particular embodiment a compound of Formula (VI),

wherein P is a protecting group PG such as Boc (tert-butoxycarbonyl), Teoc (2- (trimethylsilyl)ethoxycarbonyl) or benzyl, and wherein R₁, R3, R4, R₄,, R₄,,, R-r, m, r, n, W and Y have the meanings defined in the description, is used for the preparation of a compound of Formula (I).

In another particular embodiment a compound of Formula (Vila),

wherein L is a leaving group such as halogen, mesylate, tosylate ortriflate, and wherein R₂, q and X have the meanings defined in the description.

In another particular embodiment a compound of Formula (Vllb),

wherein R₂, q and X have the meanings defined in the description.

In another particular embodiment a compound of Formula (VIII),

wherein R₁, R₃, R*. R₄,. R₄,, Re-, m, r, n, W and Y have the meanings defined in the description, is used for the preparation of a compound of Formula (I).

In another particular embodiment there is a use of the compounds of Formula II, Ilia, 1Mb, IVa, IVb, V, VI, Vila, Vllb or VIII,

tosylate or triflate, P is a protecting group PG such as Boc (tert-butoxycarbonyl), Teoc (2-(trimethylsilyl)ethoxycarbonyl) or benzyl or P is Q and Q is

and wherein R₁, R₂, R₃, 4, R*-, Rr, R*-, m, r, n, q, W, X and Y have

the meanings defined in the description, is used for the preparation of a compound of Formula (I).

The obtained reaction products may, if desired, be purified by conventional methods, such as crystallisation and chromatography. Where the above described processes for the preparation of compounds of the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. If there are chiral centres the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.

One preferred pharmaceutically acceptable form of a compound of the invention is the crystalline form, including such form in pharmaceutical composition. In the case of salts and also solvates of the compounds of the invention the additional ionic and solvent moieties must also be non-toxic. The compounds of the invention may present different polymorphic forms, it is intended that the invention encompasses all such forms.

Another aspect of the invention refers to a pharmaceutical composition which comprises a compound according to the invention as described above according to general formula I or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. The present invention thus provides pharmaceutical compositions comprising a compound of this invention, or a pharmaceutically acceptable salt or stereoisomers thereof together with a pharmaceutically acceptable carrier, adjuvant, or vehicle, for administration to a patient. Examples of pharmaceutical compositions include any solid (tablets, pills, capsules, granules etc.) or liquid (solutions, suspensions or emulsions) composition for oral, topical or parenteral administration.

In a preferred embodiment the pharmaceutical compositions are in oral form, either solid or liquid. Suitable dose forms for oral administration may be tablets, capsules, or solutions and may contain conventional excipients known in the art such as binding agents, for example syrup, acacia, gelatine, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulfate.

The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art. The tablets may for example be prepared by wet or dry granulation and optionally coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

The pharmaceutical compositions may also be adapted for parenteral administration, such as sterile solutions, suspensions or lyophilized products in the appropriate unit dosage form. Adequate excipients can be used, such as bulking agents, buffering agents or surfactants.

The mentioned formulations will be prepared using standard methods such as those described or referred to in the Spanish and US Pharmacopoeias and similar reference texts. Administration of the compounds or compositions of the present invention may be by any suitable method, such as intravenous infusion, oral preparations, and intraperitoneal and intravenous administration. Oral administration is preferred because of the convenience for the patient and the chronic character of the diseases to be treated. Generally an effective administered amount of a compound of the invention will depend on the relative efficacy of the compound chosen, the severity of the disorder being treated and the weight of the sufferer. However, active compounds will typically be administered once or more times a day for example 1 , 2, 3 or 4 times daily, with typical total daily doses in the range of from 0.1 to 1000 mg/kg/day. The compounds and compositions of this invention may be used with other drugs to provide a combination therapy. The other drugs may form part of the same composition, or be provided as a separate composition for administration at the same time or at different time.

Another aspect of the invention refers to the use of a compound of the invention or a pharmaceutically acceptable salt or isomer thereof in the manufacture of a medicament.

Another aspect of the invention refers to a compound of the invention according as described above according to general formula I, or a pharmaceutically acceptable salt or isomer thereof, for use as a medicament for the treatment of pain. Preferably the pain is medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia. This may include mechanical allodynia or thermal hyperalgesia.

Another aspect of the invention refers to the use of a compound of the invention in the manufacture of a medicament for the treatment or prophylaxis of pain.

In a preferred embodiment the pain is selected from medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia, also preferably including mechanical allodynia or thermal hyperalgesia. Another aspect of this invention relates to a method of treating or preventing pain which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound as above defined or a pharmaceutical composition thereof. Among the pain syndromes that can be treated are medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia, whereas this could also include mechanical allodynia or thermal hyperalgesia.

The present invention is illustrated below with the aid of examples. These illustrations are given solely by way of example and do not limit the general spirit of the present invention.

General Experimental Part (Methods and Equipment of the synthesis and analysis

A process is described in Scheme 1 for the preparation of compounds of general formula I, wherein R₁, R₂, R₂, ¾, ¾·, Re, Re-, m, n, q, r, W, X and Y have the meanings defined above.

Where, L is a leaving group such as halogen, mesylate, tosylate or triflate and Z is chlorine or bromine, Q is the group indicated in a square in Scheme 1 and PG is a protecting group.

This process is carried out as described below: Step 1: The compounds of general formula IVa or IVb wherein n is 0 and W is nitrogen, are prepared by Strecker reaction of ketone derivatives of formula II with amino compounds of formula Ilia or 1Mb using a metal cyanide, preferably potassium cyanide, in the presence of an acid catalyst, in water at room temperature.

Step 2: Compounds of general formula Iva or IVb are treated with a lithium salt in situ generated from compounds of general formula V with nBuLi, in a suitable solvent, preferably in tetrahydrofuran, at a suitable temperature comprised between -78 °C and room temperature, preferably at room temperature. In a subsequent reaction, the obtained imine intermediate compound is hydrolized to ketone compounds of formula VI or I in the presence of an aqueous inorganic acid such as HCI.

For compounds of general formula VI, wherein P is a protecting group, two additional steps are necessary to obtain compounds of formula I:

Step 3: A compound of formula VIII is prepared by deprotection of a compound of formula VI. If the protecting group is benzyl the deprotection is carried out under hydrogenation conditions, with hydrogen at a pressure comprised between 1 and 10 bar, in the presence of Pd and in a suitable solvent such as methanol or ethanol, optionally in the presence of an acid such as acetic or hydrochloric acid, at a suitable temperature comprised between room temperature and the reflux temperature. Alternative hydrogenation conditions involve the treatment with dichloroethyl formate as hydrogen source, in a suitable solvent such dichloroethane, at a suitable temperature comprised between room temperature and the reflux temperature, preferably at the reflux temperature. If the protecting group is Boc, the deprotection is carried out in the presence of an inorganic acid such as HCI or trifluoroacetic acid, in a suitable solvent such as dichloromethane, at a suitable temperature comprised between room temperature and the reflux temperature. Step 4: From deprotected compounds of general formula VIII, compounds of general formula I can be prepared by reaction with suitable reagents, such as those of formula Vlla-b, using different conditions depending on the reagent nature. Thus:

The alkylation reaction with a compound of formula Vila is carried out in a suitable solvent, such as acetonitrile, dichloromethane, 1 ,4-dioxane, ethanol or dimethylformamide, preferably in acetonitrile, in the presence of an inorganic base such as K2CO3 or CS2CO3, or an organic base such as triethylamine or diisopropylethylamine, preferably K2CO3, at a suitable temperature comprised between room temperature and the reflux temperature, preferably heating, or alternatively, this reaction can be carried out in a microwave reactor. Additionally, an activating agent such as Nal or Kl can be used.

The reductive amination with a compound of formula Vllb, is carried out in the presence of a reductive reagent, preferably sodium triacetoxyborohydride, in a suitable solvent, preferably methanol, at a suitable temperature comprised between room temperature and the reflux temperature, preferably in a microwave reactor.

The process described by Steps 1 to 4 represents the general route for the

preparation of compounds of formula I. Additionally, the functional groups present in any of the positions can be interconverted using reactions known to those skilled in the art.

In some of the processes described above it may be necessary to protect the reactive or labile groups present with suitable protecting groups, such as for example Boc (tert-butoxycarbonyl), Teoc (2-(trimethylsilyl)ethoxycarbonyl) or benzyl for the protection of amino groups. The procedures for the introduction and removal of these protecting groups are well known in the art and can be found thoroughly described in the literature. In addition, a compound of formula I that shows chirality can also be obtained by resolution of a racemic compound of formula I either by chiral preparative HPLC or by crystallization of a diastereomeric salt or co-crystal. Alternatively, the resolution step can be carried out at a previous stage, using any suitable intermediate.

Compounds of formula II, Ilia, 11 lb, V, Vila and Vllb where R₁, R₂, R₅, R->, Rr, Rc, R₄,-, m, n, q, r, W, X and Y have the meanings defined above, are commercially available or can be prepared by conventional methods described in the bibliography.

EXAMPLES:

Intermediates and Examples

The following abbreviations are used in the examples:

ACN: Acetonitrile

AcOEt: Ethyl acetate

Anh: anhydrous

CH: Cyclohexane

DCM: Dichloromethane

DCE: 1 ,2-Dicloroethane

DIPEA: Λ/,N-Diisopropylethylarnine

Ex: Example h: Hour/s HPLC: High-performance liquid chromatography

INT: Intermediate

MeOH: Methanol

MS: Mass spectrometry Min: Minutes

Ret: Retention rt: Room temperature

Sat: Saturated

THF: Tetrahydrofuran Wt: Weight

The following methods were used to obtain the HPLC-MS data:

A: Column Acquity UPLC BEH C18 2.1x50 mm, 1.7 pm; flow rate 0.61 mL/min; A: NH₄HCO₃ 10mM; B: ACN; Gradient: 0.3 min in 98% A, 98% A to 0% A in 2.7 min, 2 min in 0% A, 0% A to 98% A in 0.2 min, 0.55 min in 98% A

B: Column: Acquity BEH C18 2.1x50 mm 1.7pm; flow rate 800 μΙ/min; A: NH4HCO3 10mM; B: ACN; Gradient: 0.3 min in 90% A, 90% A to 5% A in 2.7 min, 0.7 min in 5% A, 5% A to 90% A in 0.1 min, 1.2 min in 90% A Intermediate 1 A. 3-(4-Benzylpiperazin-1 -yl)-1 -methylpiperidine-3-carbonitrile.

In a 100 mL round bottomed flask, 1-methylpiperidin-3-one (0.83 g, 7 mmol) was dissolved in water (40 mL) along with sodium metabisulfite (0.7 g, 4 mmol). The mixture was allowed to stir at rt for 1 h, then 1-benzylpiperazine (1.3 mL, 7 mmol) was added. The mixture was stirred for 2 h and potassium cyanide (0.7 g, 12 mmol) was added to the reaction mixture. The reaction was stirred at rt until full conversion was achieved and the solid formed was filtered and dried, to give the title compound as a cream solid (1.24 g, yield 51%).

HPLC-MS (Method A): Ret, 1.82 min; ESI+-MS m/z, 299.3 (M+H).

This method was used for the preparation of intermediates 1B-1 H using suitable piperidones and the required piperazines:

Example 1. (3-(4-Benzylpiperazin-1-yl)-1-methylpiperidin-3-yl)(pyridin-2- yl)methanone.

a) (3-(4-Benzylpiperazin-1 -yl)-1 -methylpiperidin-3-yl)(pyridin-2-yl)methanimine.

2-Bromopyridine (0.96 mL, 10 mmol) in THF (20 mL), under argon atmosphere, was cooled down to -78 °C and n-BuLi (1.6 M in hexane, 6.5 mL, 10 mmol) was added. The reaction was kept for 30 min at this temperature and a solution of 3-(4-benzylpiperazin- 1-yl)-1-methylpiperidine-3-carbonitrile (INT 1A, 0.94 g, 3.2 mmol) was added. The reaction was slowly allowed to reach rt. and stirred overnight. The mixture was quenched with NH4CI and extracted with diethyl ether. The combined organic fractions were dried over a2S0 . The solvent was removed under reduced pressure, to give the crude title compound as oil, that was used in the following step without further purification.

HPLC-MS (Method A): Ret, 1.56 min; ESI+-MS m/z, 378.4 (M+1).

b) Title compound.

The crude imine obtained in step a (1.3 g, 3.2 mmol) was dissolved in THF (26 mL) and 3 N HCI (ca. 26 mL) was added. The reaction was stirred at rt overnight until full conversion was achieved (HPLC analysis). The mixture was made alkaline with 10% NaOH and extracted twice with AcOEt. The combined organic phases were dried over Na2SO-), filtered and concentrated to give a brown oil. The crude product was purified by flash chromatography on neutral alumina, eluents CH:AcOEt, gradient from 0 to 100% of AcOEt, to give the title compound (1 g, yield 74% over two steps).

HPLC-MS (Method A): Ret, 1.9 min; ESI⁺-MS m/z, 379.3 (M+1).

This method was used for the preparation of examples 2-6 using intermediates 1 B-1 F as starting materials:

Example 7. (3-(4-(2-lsopropoxyethyl)piperazin-1 -yl)-1 -methylpiperidin-3-yl)(pyridin-2- yl)methanone.

a) (1-Methyl-3-(piperazin-1-yl)piperidin-3-yl)(pyridin-2-yl)methanone dihydrochloride.

To a solution of (3-(4-benzylpiperazin-1-yl)-1-methylpiperidin-3-yl)(pyridin-2- yl)methanone (Ex 1 , 582 mg, 1.5 mmol,) in DCE (45 mL), dichloroethyl formate (330 μΙ_, 3 mmol) was added and the reaction mixture was heated to reflux for 4 h. After cooling down to rt, volatiles were removed under reduced pressure. MeOH (46 mL) was then added and the reaction mixture heated again to reflux for 2 h. After cooling back to rt, the solvent was removed and the brown oil thus obtained was washed several times with diethyl ether and dried in vacuum to give the crude title compound as solid, that was used in the following step without further purification (540 mg, yield 42%).

HPLC-MS (Method A): Ret, 0.99 min; ESI⁺-MS m/z, 289.2 (M+1).

b) Title compound.

2-(2-Bromoethoxy)propane (62 mg, 0.37 mmol) was added to a solution of the compound obtained in step a (90 mg, 0.25 mmol), K₂C0₃ (138 mg, 1 mmol) and Nal (9 mg, 0.060 mmol) in ACN (10 ml_). The reaction mixture was stirred at 70 °C overnight and then it was cooled down to rt. AcOEt (10 mL) and sat aqueous NaHCOs solution (10 mL) were added and the phases were separated. The organic layer was dried over Na₂S04, filtered and concentrated. The crude residue was purified by flash chromatography on neutral alumina, eluents CH/AcOEt from 0% to 100% AcOEt, to give the title compound as a yellow oil (34 mg, yield 34%).

HPLC-MS (Method A): Ret, 1.52 min; ESI+-MS m/z, 375.3 (M+1 ).

This method was used for the preparation of examples 8-9 using suitable alkylating agents:

Example 10. 1 -(3-(4-lsopentylpiperazin-1 -yl)-3-picolinoylpiperidin-1 -yl)ethanone.

a) (3-(4-lsopentylpiperazin-1-yl)piperidin-3-yl)(pyridin-2-yl)methanone

dihydrochloride.

Debenzylation of (1 -benzyl-3-(4-isopentylpiperazin-1 -yl)piperidin-3-yl)(pyridin-2- yl)methanone (Ex 2) was effected following the procedure described in Ex 7 step a. HPLC-MS (Method A): Ret, 1.95 min; ESI⁺-MS m z, 345 (M+1).

b) Title compound. A microwave vial was charged with the compound obtained in step a (130 mg, 45% purity,0.14 mmol) in 0.6 mL DCE and DIPEA (55 μί, 0.3 mmol).The mixture was stirred 15 min, acetic anhydride (0.6 mL, 11 mmol) was added and the vial was sealed and subjected to microwave irradiation for 10 min at 120 °C. The crude was partitioned between AcOEt and sat aqueous solution of NaHC0₃. The organic layer was dried over Na₂SC>4, filtered and concentrated. The crude residue was purified by flash chromatography on neutral alumina, eluents CH/AcOEt from 0% to 100% AcOEt, to give the title compound (40 mg, yield 66%).

HPLC-MS (Method B): Ret, 2.17 min; ESI+-MS m/z, 387 (M+1).

Example 11. ((1-Benzoyl-3-(4-isopentylpiperazin-1-yl)piperidin-3-yl)(pyridin-2- yl)methanone.

(3-(4-lsopentylpiperazin-1-yl)piperidin-3-yl)(pyridin-2-yl)methanone dihydrochloride (compound obtained in Ex. 10 step a, 448 mg, 0.99 mmol) was dissolved in anh DCM (20mL) and DIPEA (0.7 mL, 4 mmol) and benzoyl chloride (0.25 mL, 2.2 mmol) were added. The reaction mixture was stirred at rt overnight. Then it was diluted with DCM and washed with sat aqueous solution of NaHC0₃. The organic layer was dried over Na₂S04, filtered and concentrated. The crude residue was purified by preparative HPLC (column X-Bridge C18, ACN: NH4HCO3 10 mM from (2:98 to 95-5), flow 20 ml/min, rt) to give the title compound (50 mg, yield 11%).

HPLC-MS (Method A): Ret, 2.15 min; ESI+-MS m/z, 449.3 (M+1). This method was used for the preparation of examples 12-14 using suitable starting materials.

Example 15. (4-(4-lsopentylpiperazin-1 -yl)-2,2-dimethylpiperidin-4-yl)(pyridin-2- yl)methanone.

a) (4-(4-lsopentylpiperazin-1-yl)-2,2-dimethylpiperidin-4-yl)(pyridin-2-yl)methanol (1 -Benzyl-4-(4-isopentylpiperazin-1 -yl)-2,2-dimethylpiperidin-4-yl)(pyridin-2- yl)methanone (Ex 5, 74 mg, 0.160 mmol) was dissolved in MeOH (5 mL) and ammonium formate (68 mg, 1.1 mmol) and Pd (16 mg, 50% Wt) were added. The suspension was stirred under N₂ atmosphere at 110 °C overnight. The reaction mixture was filtered through celite, washed with MeOH and concentrated, to give the title product as golden oil (70 mg, quantitative yield).

HPLC-MS (Method A): Ret, 1.18 min; ESI⁺-MS m/z, 374 (M+1).

b) Title compound.

The compound obtained in step a (62 mg, 0.16 mmol) was dissolved in DCM (4 mL) under nitrogen atmosphere at 0 °C and Dess-Martin periodinane (DMP, 1.1 mL, 0.32 mmol) was added. The reaction mixture was allowed to reach rt and stirred overnight. After that it was diluted with DCM and washed with 10% NaOH. The aqueous layer was extracted several times and the combined organic phases were dried over Na₂S0₄, filtered and concentrated. The crude residue was purified by preparative HPLC (column X-Bridge C18, ACN: NH4HCO3 10 mM from (2:98 to 95-5), flow 20 ml/min, rt) to give the title compound (8 mg, yield 13 %).

HPLC-MS (Method A): Ret, 2.05 min; ESI+-MS m/z, 373 (M+1). Example 16. 1 -(4-(4-lsopentylpiperazin-1 -yl)-2,2-dimethyl-4-picolinoylpiperidin-1 - yl)ethanone.

Amide formation was done following the procedure described in Ex 10 step b and using (4-(4-isopentylpiperazin-1-yl)-2,2-dimethylpiperidin-4-yl)(pyridin-2-yl)methanone (Ex 18) as starting material.

HPLC-MS (Method A): Ret, 2.01 min; ESI⁺-MS m/z, 415 (M+1).

Example 17. (1 -Benzoyl-4-(4-isopentylpiperazin-1 -yl)-2,2-dimethylpiperidin-4- yl)(pyridin-2-yl)methanone.

Title compound was obtained following the procedure described in Ex 11 and using (4- (4-lsopentylpiperazin-1 -yl)-2,2-dimethylpiperidin-4-yl)(pyridin-2-yl)methanone (Ex 18) as starting material. HPLC-MS (Method A): Ret, 2.47 min; ESI⁺-MS m/z, 477 (M+1).

This method was used for the preparation of example 21 using Ex 18 as starting material and propyonyl chloride as acylating agent:

Example 19. 4-(4-lsopentylpiperazin-1-yl)-A/_l2_l2-trimethyl-4-picolinoylpiperidine-1- carboxamide.

Over a solution of (4-(4-isopentylpiperazin-1-yl)-2,2-dimethylpiperidin-4-yl)(pyridin-2- yl)methanone (Ex 15, 72 mg, 0.15 mmol) in anh DCM (5 ml) at 0 °C, DIPEA (100 μΙ, 0.61 mmol) and 2,5-dioxopyrrolidin-l-yl methylcarbamate (53 mg, 0.31 mmol ) were added. The solution was allowed to reach rt overnight, after which the reaction was quenched with cold water/ ice and extracted with DCM (3x10 mL). The combined organic layers were washed several times with water, dried over Na₂S0₄and concentrated. The crude residue was purified by flash chromatography, eluents DCM/ MeOH from 100:0 to 95:5, to give the title compound as yellow oil (25 mg, yield 38%).

HPLC-MS (Method B): Ret, 2.26 min; ESI+-MS m/z, 430.3 (M+1).

Example 20. (4-(4-lsopentylpiperazin-1-yl)-1 ,2,2-trimethylpiperidin-4-yl)(pyridin-2- yl)methanone

a) (4-(4-lsopentylpiperazin-1 -yl)-1 ,2,2-trimethylpiperidin-4-yl)(pyridin-2-yl)methanol. (4-(4-lsopentylpiperazin-1 -yl)-2,2-dimethylpiperidin-4-yl)(pyridin-2-yl)methanol

(obtained in Ex. 15, step a, 70 mg, 0.18 mmol) was dissolved, under argon atmosphere, in MeOH (2 mL). Formaldehyde (13.3 M, 250 μΙ, 3.2 mmol) and sodium triacetoxyborohydride (91 mg, 0.43 mmol) were added. The suspension was stirred at rt overnight and then, more sodium triacetoxyborohydride was added and stirred for 24 h more. The reaction mixture was slowly poured into sat aqueous solution of NaHC0₃at 0 °C. The reaction was filtered, washed with water several times and dried to afford the title compound (61 mg, 74% purity, yield 62%).

HPLC-MS (Method A): Ret, 1.33 min; ESI⁺-MS m/z, 389 (M+1). b) Title compound.

The compound obtained in step a) was oxidized using the procedure described in Ex 15 step b, to give the title compound.

HPLC-MS (Method A): Ret, 1.78 min; ESI⁺-MS m/z, 387 (M+1).

Example 21. (3-(4-benzylpiperazin-1 -yl)-1 -ethylpiperidin-3-yl)(pyridin-2-yl)methanone

Example 21 was prepared according to the procedure described in example 1 , using intermediate 1H as starting material. HPLC-MS (Method A): Ret. 2.11 min: ESI+-MS m/z. 393 (M+1).

Example 22. 4-ethvl-6-(1-isopentvlpiperidin-4-vl)-6-picolinovlmorpholin-3-one

HPLC-MS (Method A): Ret. 1.76 min: ESI+-MS m/z. 388 (M+1).

Table of Examples with binding to the u-opioid Receptor and the σι-Receptor: BIOLOGICAL ACTIVITY Pharmacological study

Human σ₁ receptor radioligand assay

To investigate binding properties of test compounds to human σ₁ receptor, transfected HEK-293 membranes and [³H](+)-pentazocine (Perkin Elmer, NET-1056), as the radioligand, were used. The assay was carried out with 7 ig of membrane suspension, 5 nM of [³H](+)-pentazocine in either absence or presence of either buffer or 10 μΜ Haloperidol for total and non-specific binding, respectively. Binding buffer contained Tris-HCI 50 mM at pH 8. Plates were incubated at 37 °C for 120 minutes. After the incubation period, the reaction mix was then transferred to Multiscreen HTS, FC plates (Millipore), filtered and plates were washed 3 times with ice-cold 10 mM Tris-HCL (pH7.4). Filters were dried and counted at approximately 40% efficiency in a MicroBeta scintillation counter (Perkin-Elmer) using EcoScint liquid scintillation cocktail. Preferably, transfected HEK-293 membranes (7 μg) were incubated with 5 nM of [³H](+)-pentazocine in assay buffer containing Tris-HCI 50 mM at pH 8. NBS (nonspecific binding) was measured by adding 10 μΜ Haloperidol. The binding of the test compound was measured at five different concentrations. Plates were incubated at 37 °C for 120 minutes. After the incubation period, the reaction mix was then transferred to Multiscreen HTS, FC plates (Millipore), filtered and plates were washed 3 times with ice-cold 10 mM Tris-HCL (pH7.4). Filters were dried and counted at approximately 40% efficiency in a MicroBeta scintillation counter (Perkin-Elmer) using EcoScint liquid scintillation cocktail.

Human u-opioid receptor radioligand assay To investigate binding properties of test compounds to human μ-opioid receptor, transfected CHO-K1 cell membranes and [³H]-DAMGO (Perkin Elmer, ES-542-C), as the radioligand, were used. The assay was carried out with 20 [ig of membrane suspension, 1 nM of [³H]-DAMGO in either absence or presence of either buffer or 10 μΜ Naloxone for total and non-specific binding, respectively. Binding buffer contained Tris-HCI 50 mM, MgCI2 5 mM at pH 7.4. Plates were incubated at 27°C for 60 minutes. After the incubation period, the reaction mix was then transferred to Multiscreen HTS, FC plates (Millipore), filtered and plates were washed 3 times with ice-cold 10 mM Tris- HCL (pH 7.4). Filters were dried and counted at approximately 40% efficiency in a MicroBeta scintillation counter (Perkin-Elmer) using EcoScint liquid scintillation cocktail. Preferably, transfected CHO-K1 cell membranes (20 μg) were incubated with 1 nM of [³H]-DAMGO in assay buffer containing Tris-HCI 50 mM, MgCI2 5 mM at pH 7.4. NBS (non-specific binding) was measured by adding 10 μΜ Naloxone. The binding of the test compound was measured at five different concentrations. Plates were incubated at 27°C for 60 minutes. After the incubation period, the reaction mix was then transferred to Multiscreen HTS, FC plates (Millipore), filtered and plates were washed 3 times with ice-cold 10 mM Tris-HCL (pH 7.4). Filters were dried and counted at approximately 40% efficiency in a MicroBeta scintillation counter (Perkin-Elmer) using EcoScint liquid scintillation cocktail.

Results:

The following scale has been adopted for representing the binding to the σ₁ receptor and the μ-opioid receptor expressed as K,:

+ Both Ki-μ and Κ,-σ₁ >= 1000 nM

++ One Ki <1000 nM while the other Kj is >=1000 nM

+++ Both Ki-μ and Κκτι < 1000 nM

++++ Both Ki-μ and Κι-σ₁ < 500 nM

All compounds prepared in the present application exhibit binding to the receptor and the μ-opioid receptor, in particular the following binding results are shown:

Claims

CLAIMS:

1. Compound of general Formula (I):

O

(I) wherein m is 0, 1 or 2; r is 0, 1 or 2; n is 0, 1 , 2 or 3; q is 0, 1 , 2 or 3;

X is a bond or -0-; W is -CH- or nitrogen;

Y is a bond or -0-; with the proviso that when Y is -0-, then m is 1 or 2; R₁ is selected from substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; R₂ is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; R3 is selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R5 and - C(0)NR₅R₅-; wherein R₅ and R_5' are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;

R₄ and R4' are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, R4 and R , may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; alternatively R₄ and R₄, may form together with the carbon atom to which they are attached a carbonyl group;

RA, and R4-are independently selected from hydrogen, substituted or unsubstituted C_1- β alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl; alternatively, Rr and R """ may form together with the carbon atom to which they are attached a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof;

2. Compound according to claim 1 wherein the compound of Formula (I) is a compound of Formula (I^,), (I²'), (I³'), (l⁴'), (I⁵⁸'). (I^5b"), C⁶⁸') or (l^eb'),

q \

R₂

a compound of Formula (l⁴')

compound of Formula (I⁵⁸')

or a compound of Formula (l^5b')

a compound of Formula (l^6a")

or a compound of Formula (l^eb')

whereinR₆ and R₆' are independently selected from halogen, -R₁₁, -OR₁₁, -N0_2> -NR₁₁R₁r, -NR₁₁C(0)R₁r. -NR₁₁S(0)₂R₁r, -S(0)₂NR₁₁R₁r, -NR₁,C(0)NR₁₁ R₁r, -SR₁₁ , -S(0)R₁₁, -S(0)₂R₁₁, -CN, haloalkyl, haloalkoxy, -C(0)OR₁₁, - C(0)NR₁₁R₁r, -OCH₂CH20R₁₁, -NR₁₁S(0)₂NR₁₁ R₁₁ - and -C(CH₃)₂OR₁₁; and R₁₁, R₁₁,,and R₁₁, are independently selected from hydrogen, unsubstituted C_1-6 alkyl, unsubstituted C_2-6 alkenyl and unsubstituted C_2-6 alkynyl.

3. Compound according to any one of claims 1 or 2 wherein R2 is selected from hydrogen, substituted or unsubstituted C₁-β alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; preferably selected from substituted or unsubstituted C1-8 alkyl and substituted or unsubstituted aryl; more preferably selected from substituted or unsubstituted isopropyl, substituted or unsubstituted isobutyl and substituted or unsubstituted phenyl.

4. Compound according to any one of claims 1 to 3 wherein R3 is selected from hydrogen, substituted or unsubstituted C₁-β alkyl, substituted or unsubstituted C_2-6 alkenyl, substituted or unsubstituted C_2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheterocyclyl, -C(0)R₅, -S(0)₂R₅ and -C(0)NR₅R₅-; wherein R5 and R₅ are independently selected from hydrogen, substituted or unsubstituted C_1-6 alkyl, substituted or unsubstituted C_2-6 alkenyl and substituted or unsubstituted C_2-6 alkynyl , substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; preferably R3 is selected from hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted 1-propionyl, substituted or unsubstituted benzyl, substituted or unsubstituted acetyl, substituted or unsubstituted benzoyl, substituted or unsubstituted -S(0)₂-methyl and substituted or unsubstituted - C(0)NH-methyl; 5. Compound according to any one of claims 2 to 4 whereinR₆ and R₆- are both hydrogen.

6. Compound according to any one claims 1 to 5 wherein q is 0 or 1.

7. Compound according to any one claims 1 to 6 wherein m is 1 or 2, and r is 0 or 1.

8. Compound according to any one of claims 1 to 7 wherein the compound is selected from

Compound according to claim 1 wherein the compound of Formula (I) is compound of Formula (I⁷'),

10. Compound according to claim 1 or 9 wherein the compound of Formula (I) is a compound of Formula (I⁸'),

11. Process for the preparation of a compound according to Formula (I),

(I). wherein compounds of general formula IVb

wherein compounds of general formula VIII

are reacted with a compound of formula Vila

are reacted with a compound of formula Vllb

in the presence of a reductive reagent, in a suitable solvent, at a suitable temperature, preferably in a microwave reactor, wherein

Z is chlorine or bromine,

P is Q, and Q is

wherein R₁, f¾, R₂, R4, ¾·, R₄,-, R₄,,,, m, n, q, r, X, W and Y have the meanings defined in the description.

Use of compounds of Formula II, Ilia, 1Mb, IVa, IVb, V, VI, Vila, Vllb or VIII,

such as halogen, mesylate, tosylate or inflate, P is a protecting group PG such as Boc (tert-butoxycarbonyl), Teoc (2-(trimethylsilyl)ethoxycarbonyl) or benzyl or P is Q and Q is

and wherein R₁, R₂, R_3l R4, R₄,. R-v, R ·, m, r, n, q, W, X and

Y have the meanings defined in the preceding claims, for the preparation of a compound of Formula (I).

13. A pharmaceutical composition which comprises a compound of Formula (I) as defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. 14. A compound of Formula (I) as defined in any one of claims 1 to 10 for use as a medicament.

15. A compound of Formula (I) as defined in any one of claims 1 to 10 for use as a medicament; preferably for use as a medicament for the treatment of pain, especially medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia or hyperalgesia.